[
    {
        "sen": [
            "Some publications have reported highest risk of severe complications of 2019 novel coronavirus disease (COVID‐19) in cancer patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To date, quarantine is the only recommended preventive attitude against COVID‐19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "High proportion of asymptomatic patients, the absence of validated serological testing and the limitations of systematic mass testing by reverse transcription‐polymerase chain reaction (RT‐PCR), hamper the control of COVID‐19 outbreak."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We report a strategy of systematic detection of COVID‐19 symptoms with patient‐reported questionnaire in cancer patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We estimated the incidence rate of COVID‐19 among cancer patients at 1.5%, consistently with previous results."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This might be underestimated due to asymptomatic forms of COVID‐19, low specificity of COVID‐19 symptoms in context of malignancies and false‐negative results of RT‐PCR assay."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "One of limitation in our study is the lack of screening of digestive symptoms, potentially compatible with COVID‐19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Most of screened patients were not male (75.7%) and had no comorbidity (55.6%), factors predisposing to COVID‐19 and severe forms."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Finally, we excluded patients with thoracic and hematological malignancies, also at risk of COVID‐19 and severe events."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Nine patients were diagnosed with COVID‐19 and none developed severe form, contrary to other studies including mostly cancer survivors or lung cancer patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            ", ",
            " Given the absence of severe form of COVID‐19, we did not study biological prognostic factors, probably poorly specific in cancer patients."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Large‐scale data are needed to further explore risk factors of COVID‐19 severity in this population."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "More than 10,000 globally sourced SARS-CoV-2 genomes are publicly available, and powerful data sharing and analysis platforms like the ",
            "Global Initiative on Sharing All Influenza Data (GISAID) EpiCoV",
            " database [13] and ",
            "Nextstrain",
            " [14] enable the collaborative analysis of viral population structure on a global level."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 135,
                "end": 198,
                "name": "Global Initiative on Sharing All Influenza Data (GISAID) EpiCoV"
            },
            false,
            {
                "id": "T2",
                "type": "Repository",
                "start": 217,
                "end": 227,
                "name": "Nextstrain"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The current emergency of COVID‐19 arose after the end of 2019 in Wuhan (China) and was officially declared a pandemic by the World Health Organization (WHO) on 11 March 2020."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The first report in the South American region of a patient with COVID‐19 was declared by Brazil, whereas Venezuela and Uruguay were the ultimate nations to confirm their patient zero."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "According to the situation report (No. 102) of the WHO, Brazil has the highest number of COVID‐19 confirmed cases (78 162) and deceases (5466) due to this disease, followed by Peru with 33 931 and 943, respectively."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Analyses were performed to obtain an overview of genomic SARS‐CoV‐2 mutations of circulating strains in South America; we download a total of 30 complete genomes of South American countries from the ",
            "GISAID",
            " (",
            "https://www.gisaid.org/",
            ") database."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 774,
                "end": 780,
                "name": "GISAID"
            },
            false,
            {
                "id": "T2",
                "type": "URL",
                "start": 782,
                "end": 805,
                "name": "https://www.gisaid.org/"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T1",
                "end": "T2"
            }
        ]
    },
    {
        "sen": [
            "Additionally, we downloaded 688 genomes from the ",
            "GISAID",
            " database,",
            " the genomes were complete (>29 000 bp) and with high coverage according to this public resource."
        ],
        "lab": [
            false,
            {
                "id": "T3",
                "type": "Dataset",
                "start": 866,
                "end": 872,
                "name": "GISAID"
            },
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Since the first officially reported patient in South America in Brazil, other countries have been informing COVID‐19 cases."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "However, the ",
            "GISAID SARS‐CoV‐2",
            " portal (URL at: ",
            "https://www.gisaid.org/epiflu-applications/next-hcov-19-app/",
            ") depicts the close relationship between an isolate from Oceania (",
            "EPI ISL 417211",
            ") and the strain sequenced in Ecuador."
        ],
        "lab": [
            false,
            {
                "id": "T4",
                "type": "Dataset",
                "start": 1118,
                "end": 1135,
                "name": "GISAID SARS‐CoV‐2"
            },
            false,
            {
                "id": "T5",
                "type": "URL",
                "start": 1152,
                "end": 1212,
                "name": "https://www.gisaid.org/epiflu-applications/next-hcov-19-app/"
            },
            false,
            {
                "id": "T6",
                "type": "AccessionNumber",
                "start": 1278,
                "end": 1292,
                "name": "EPI ISL 417211"
            },
            false
        ],
        "rel": [
            {
                "id": "R2",
                "bool": true,
                "head": "T4",
                "end": "T5"
            },
            {
                "id": "R3",
                "bool": true,
                "head": "T4",
                "end": "T6"
            }
        ]
    },
    {
        "sen": [
            "After more than 4 months of the COVID‐19 pandemics with genomic information of SARS‐CoV‐2 around the globe, there are more than 1000 complete genomes of this virus."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We used 691 genomes from the ",
            "GISAID",
            " database."
        ],
        "lab": [
            false,
            {
                "id": "T7",
                "type": "Dataset",
                "start": 1525,
                "end": 1531,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The ongoing COVID-19 pandemic is the greatest health-care challenge of this generation."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To facilitate the epidemiological tracking of SARS-CoV-2, researchers worldwide have created various web-portals and tools, such as the Johns Hopkins University COVID-19 dashboard."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "An unprecedented effort to make COVID-19-related data accessible in near real-time has resulted in more than 25 000 publicly available genome sequences of SARS-CoV-2 on ",
            "Global Initiative on Sharing All Influenza Data (GISAID)",
            "."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 438,
                "end": 494,
                "name": "Global Initiative on Sharing All Influenza Data (GISAID)"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To address this gap, we have developed an accessible application, the COVID-19 Genotyping Tool (CGT)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A video demonstration of CGT is available in appendix 1."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "CGT uses publicly deposited SARS-CoV-2 consensus genome sequences from the ",
            "GISAID EpiCoV™",
            " database, and summarises relevant information through salient visualisations, including Uniform Manifold Approximation and Projection (UMAP), Minimum Spanning Trees (MST) of sequence networks, and allele frequencies of annotated high-prevalence non-synonymous Single-Nucleotide Polymorphisms (SNPs) within structural protein-coding genomic regions (envelope, membrane, nucleocapsid, and spike proteins; figure",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T2",
                "type": "Dataset",
                "start": 730,
                "end": 744,
                "name": "GISAID EpiCoV™"
            },
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "New sequencing data from ",
            "GISAID",
            " are added to CGT once a week."
        ],
        "lab": [
            false,
            {
                "id": "T3",
                "type": "Dataset",
                "start": 1183,
                "end": 1189,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We use UMAP and network analysis instead of phylogenetics because of a faster computation time and ease of interpretability for large datasets."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Our results indicate that there are distinct viral isolate clusters for SARS-CoV-2 sequences uploaded to ",
            "GISAID",
            "."
        ],
        "lab": [
            false,
            {
                "id": "T4",
                "type": "Dataset",
                "start": 1469,
                "end": 1475,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Our novel tool is accessible to those who might not be trained in bioinformatics and epidemiological analysis, and thus it serves as a platform for aiding in a pivotal aspect of the global research effort against the COVID-19 pandemic."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In the U. S and UK, the COVID Symptom tracker app developed with the ",
            "Coronavirus Pandemic Epidemiology Consortium (COPE)",
            " is being widely used to track COVID-related exposure and infections. [12]",
            "Our current project aims to provide a systematic review of the literature on mobile applications with multiple function including: information dissemination (ID), ID with symptom checking (SSC), contact tracing alone, SSC, training health care workers, disinfection checklist, and service Apps around COVID-19."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 69,
                "end": 120,
                "name": "Coronavirus Pandemic Epidemiology Consortium (COPE)"
            },
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Our systematic review was registered with ",
            "PROSPERO",
            " (CRD ",
            "42020180878",
            "), consisted of a mixed methods study where we provide an overview of smartphone applications designed for COVID-19 through both a literature search as well as a search of mobile platforms for applications."
        ],
        "lab": [
            false,
            {
                "id": "T2",
                "type": "Repository",
                "start": 548,
                "end": 556,
                "name": "PROSPERO"
            },
            false,
            {
                "id": "T3",
                "type": "AccessionNumber",
                "start": 562,
                "end": 573,
                "name": "42020180878"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T2",
                "end": "T3"
            }
        ]
    },
    {
        "sen": [
            "We limited our search to applications released or updated for COVID-19 till May 5th, 2020 and screened these applications for their title, description of the application on mobile platforms, its functions around COVID-19 and then completed a comprehensive assessment of these mobile applications (Fig. 1a)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Due to rapidly evolving nature of the COVID-19 pandemic and language restrictions, we limited our search to the United States, United Kingdom and India."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A systematic search was conducted on ",
            "PubMed",
            " (Medline), ",
            "Cochrane central register for controlled trials",
            ", ",
            "Google Scholar",
            " and ",
            "Turning Research Into Practice",
            " medical database from 9-10th of May 2020 to identify peer-reviewed publications and grey literature on the utility of smartphone applications in the Covid-19 pandemic and help aid our ongoing assessment of mobile platforms. [16]",
            "Apps were classified based on their key functions- ID (n = 18), ID with tracking of individuals (n = 9), or ID with SSC (n = 15), contact tracing alone (n = 8), SSC (n = 7), training of healthcare workers (n = 3), disinfection checklist (n = 1), and service apps [Delivery or fund-raising] (n = 2)."
        ],
        "lab": [
            false,
            {
                "id": "T4",
                "type": "Repository",
                "start": 1277,
                "end": 1283,
                "name": "PubMed"
            },
            false,
            {
                "id": "T5",
                "type": "Repository",
                "start": 1295,
                "end": 1342,
                "name": "Cochrane central register for controlled trials"
            },
            false,
            {
                "id": "T6",
                "type": "Repository",
                "start": 1344,
                "end": 1358,
                "name": "Google Scholar"
            },
            false,
            {
                "id": "T7",
                "type": "Repository",
                "start": 1363,
                "end": 1393,
                "name": "Turning Research Into Practice"
            },
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The most downloaded and reviewed app on the Google play store (GPS) was Aarogya Setu developed by the Government of India (50,000,000+ downloads and 343,842 reviews), with a government mandate for download by all Indians especially those who travel or are diagnosed with COVID-19, with a GPS star rating of 4.6 out of 5 (Supplementary Table 2)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition to providing self-screening technology, it displays alerts of COVID-19 patients diagnosed within a 500 m, 1, 2, 5, and 10-km radius of the user which is a useful tool to understand the disease load in the proximity of an individual."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "For example, those articles which focused on specialty practice during COVID-19 and telemedicine, smartphone enabled technology that did not involve an application, or studies that utilized apps to assess for mental health outcomes among COVID-19 patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The more descriptive studies reviewed the evidence of the utility of smartphone apps for COVID-19 based on countries’ experiences (Table 2)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Only one application included in our study, The COVID-19 Symptom Tracker mobile application, conducted an observational study to provide scientific evidence of the app’s utility."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Important results in their study demonstrated that the app could predict in advance the COVID-19 incidence of a region. [17]",
            "Further, our study provides a comprehensive assessment of all mobile applications across three regions which are currently experiencing rapidly rising burden of COVID-19 related cases and deaths and hence, identifying the key scientific features of mobile applications that should be used in design and engagement remains very crucial to sustained public health efforts aimed at mitigating this disaster."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The global impact of COVID-19 pandemic has led to a rapid development and utilization of mobile health applications."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Here we provide an overview of mobile applications being currently utilized for COVID-19 and their assessment using the Mobile Application Rating Scale."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We performed a systematic review of the literature and mobile platforms to assess mobile applications currently utilized for COVID-19, and a quality assessment of these applications using the Mobile Application Rating Scale (MARS) for overall quality, Engagement, Functionality, Aesthetics, and Information."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Our search identified 63 apps that are currently being used for COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "18 apps were developed for sharing up to date information on COVID-19, and 8 were used for contact tracing while 9 apps showed features of both."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "As of May 23, 2020, over 5100,000 confirmed cases of Coronavirus Disease 2019 (COVID-19) and 330,000 deaths were reported globally [3], with over 200 countries impacted [4], [5], [6], [7]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "ACE2 has also been shown recently as the cellular receptor for SARS-CoV-2 in virological studies or bioinformatic analyses (PMID: ",
            "32015508",
            ", ",
            "32142651",
            ") [9]."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "AccessionNumber",
                "start": 319,
                "end": 327,
                "name": "32015508"
            },
            false,
            {
                "id": "T2",
                "type": "AccessionNumber",
                "start": 329,
                "end": 337,
                "name": "32142651"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The S gene sequence of SARS-CoV-2 (",
            "GISAID",
            ", No. ",
            "EPI_ISL_402119",
            ") and SARS-CoV (",
            "GenBank",
            " No. ",
            "AY278489.2",
            ") were codon-optimized for expression in human cells."
        ],
        "lab": [
            false,
            {
                "id": "T3",
                "type": "Dataset",
                "start": 379,
                "end": 385,
                "name": "GISAID"
            },
            false,
            {
                "id": "T4",
                "type": "AccessionNumber",
                "start": 391,
                "end": 405,
                "name": "EPI_ISL_402119"
            },
            false,
            {
                "id": "T5",
                "type": "Repository",
                "start": 421,
                "end": 428,
                "name": "GenBank"
            },
            false,
            {
                "id": "T6",
                "type": "AccessionNumber",
                "start": 433,
                "end": 443,
                "name": "AY278489.2"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T3",
                "end": "T4"
            },
            {
                "id": "R2",
                "bool": true,
                "head": "T5",
                "end": "T6"
            }
        ]
    },
    {
        "sen": [
            "SARS-CoV-2 was added to the cells (200 50% tissue culture infective dose, TCID50)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The Ct value of the measured sample was analyzed with the standard curve to calculate the corresponding TCID50 value of the sample."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To test whether hACE2 is required for SARS-CoV-2 infection, we infected Vero cells with 50 TCID50 of live SARS-CoV-2 virus in the presence of various concentrations of recombinant ACE2, as a soluble form of ACE2-Fc [14]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Vaccines inducing broad and sustained immunity could offer effective protection against infectious diseases such as COVID-19 [19,20]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Unfortunately, there are currently no approved vaccines available against any human coronavirus, despite the huge medical, social and economic impacts imposed by the SARS, MERS, and the COVID-19 pandemics."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Developing a vaccine, ideally a universal prophylactic effective against coronaviruses, will be extremely useful for combating the ongoing COVID-19 pandemic as well as future outbreaks caused by SARS-CoV variants and possibly other coronaviruses."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Therefore, taking into account all available data in SARS-CoV infection and considering SARS-CoV-2 as a virus with similar characteristics and immunopathogenic effects to SARS-Co-V, it may be hypothesised that the deleterious events in patients with the most severe forms of the COVID-19 are the results both of an excessive or inadequate immune response of the host(."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Currently, multiple studies have identified a wide range of neurological deficits associated with COVID-19 [1], reflecting both immune-mediated process involving the development [2] and parenchymal injury [3]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Furthermore, a recent study by Lu and colleagues demonstrated that microstructural changes in the cerebral parenchyma can occur during the recovery phase from COVID-19 [4], indicating that the onset of CNS damage can be asynchronous with systemic manifestations and the typically salient severe respiratory disease."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To evaluate metagenomic approaches in the context of the current SARS-CoV-2 epidemic, laboratory-confirmed positive and negative samples from Seattle, Washington were evaluated by metagenomic sequencing, with comparison to a 2019 reference genomic database created before the emergence of SARS-CoV-2."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The amino acid sequences of SARS‐CoV‐2 genome–associated proteins, that is, ORF1ab (which is a complex of the following proteins: 5′‐untranslated region, nsp‐2, nsp‐3, nsp‐4, 3C‐like protease, nsp‐6, nsp‐7, nsp‐8, nsp‐9, nsp‐10, RNA‐dependent RNA polymerase [nsp‐12], helicase [nsp13], 3′‐5′ exonuclease [nsp‐14], endoRNase [nsp‐15], and o‐ribose methyltransferase [nsp‐16]), surface glycoprotein “S,” ORF‐3a, Envelope protein “E,” Membrane glycoprotein “M,” ORF‐6, ORF‐7, ORF‐8, Nucleocapsid phosphoprotein “N” and ORF‐10, were retrieved from the ",
            "National Center for Biotechnology Information",
            " database."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 548,
                "end": 593,
                "name": "National Center for Biotechnology Information"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Both the servers are recently updated versions over previously used CD4 epitope prediction servers with improved accuracy, trained on extended datasets."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The tertiary structure of Toll‐like receptor 3 (TLR‐3) was retrieved from the ",
            "Protein Data Bank",
            " with ID: ",
            "2A0Z",
            "."
        ],
        "lab": [
            false,
            {
                "id": "T2",
                "type": "Repository",
                "start": 835,
                "end": 852,
                "name": "Protein Data Bank"
            },
            false,
            {
                "id": "T3",
                "type": "AccessionNumber",
                "start": 862,
                "end": 866,
                "name": "2A0Z"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T2",
                "end": "T3"
            }
        ]
    },
    {
        "sen": [
            "For diagnosis of coronavirus disease 2019 (COVID-19), a SARS-CoV-2 virus-specific reverse transcriptase polymerase chain reaction (RT–PCR) test is routinely used."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "However, this test can take up to 2 d to complete, serial testing may be required to rule out the possibility of false negative results and there is currently a shortage of RT–PCR test kits, underscoring the urgent need for alternative methods for rapid and accurate diagnosis of patients with COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In this study, we used artificial intelligence (AI) algorithms to integrate chest CT findings with clinical symptoms, exposure history and laboratory testing to rapidly diagnose patients who are positive for COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In a test set of 279 patients, the AI system achieved an area under the curve of 0.92 and had equal sensitivity as compared to a senior thoracic radiologist."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The AI system also improved the detection of patients who were positive for COVID-19 via RT–PCR who presented with normal CT scans, correctly identifying 17 of 25 (68%) patients, whereas radiologists classified all of these patients as COVID-19 negative."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "When CT scans and associated clinical history are available, the proposed AI system can help to rapidly diagnose COVID-19 patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Coronavirus disease 2019 (COVID-19) is a newly recognized illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which firstly emerged in December 2019 in the city of Wuhan in Hubei province, China."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "As of 29 February 2020, a cumulative total of 79 394 COVID-19 cases were reported in China, which led to 2838 deaths, according to the report of the World Health Organization–China Joint Mission on Coronavirus Disease 2019 (COVID-19) [1]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We hypothesized that a genetic variant of the interferon-induced transmembrane protein 3 (IFITM3) gene (IFITM3) was associated with the severity of COVID-19, specifically the single-nucleotide polymorphism rs12252."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "It is currently unknown whether IFITM3 shows genetic association with the severity of COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To investigate whether the IFITM3 variant was associated with disease severity, we recruited a cohort of hospitalized patients with laboratory-confirmed COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "COVID-19 was diagnosed according to the diagnosis and treatment of COVID-19 recommended by the National Health Commission of China [6]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Mild disease was defined as COVID-19 with the presence of fever, respiratory symptoms, and pneumonia at imaging."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Severe disease was defined as COVID-19 with the additional presence of significant respiratory distress (respirations, >30/min), blood oxygen saturation <93%, ratio of arterial oxygen pressure to fraction of inspired oxygen <300 mm",
            "To determine whether the homozygous C-allele carriers associate with the severity of COVID-19, we genotyped the cohort by sequencing a 300–base pair locus spanning rs12252."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These findings require further validation but represent important early evidence in a carefully phenotyped cohort for a role of IFITM3 in the severity of COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Larger cohort studies are needed to confirm this genetic association with severity of COVID-19, but the data presented here support the need for such genetic analyses in different global populations, with the opportunity for early targeted intervention in persons at risk if robust genetic biomarkers can be established and potential therapeutic targets highlighted."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Abstract  A major unanswered question in the current global coronavirus disease 2019 (COVID-19) outbreak is why severe disease develops in a small minority of infected individuals."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Here we link replication of coronaviruses, including SARS-CoV-2, the coronavirus disease 2019 (COVID-19)-causing virus, with cytoskeleton-dependent signalling and 3D genome organization."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Three-week-old male BALB/c mice were inoculated with 100 μL of PHEV (104.45 TCID50/0.1 mL) by the intranasal route, and their brain tissues were harvested at 3 and 5 dpi."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The pandemic of COVID-19, caused by the RNA coronavirus SARS-CoV2 has spread over 200 countries and infected millions of people worldwide [1,2]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The rapid spread of COVID-19 across various countries opens an intriguing question whether the variations in genome sequences of the novel coronavirus are contributing to the variation of infection and mortality rate [5,6]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Having this question in mind, with the reference to the Wuhan based genome ",
            "NC_045512",
            ", missense mutations were identified in the SARS-CoV2 genomes of the COVID-19 affected Indian patients."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "AccessionNumber",
                "start": 444,
                "end": 453,
                "name": "NC_045512"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This study of mutations in the SARS-CoV2 genomes of 128 COVID-19 affected Indian patients has been carried out."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The following Table 2, Table 3, Table 4, Table 5",
            "adumbrate all the missense mutations along with silent mutations across the 128 virus genomes from Indian COVID-19 affected patients."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This may suggest that designing a therapeutic approach against ORF6, ORF10 and E genes may have a beneficial effect in controlling COVID-19 pandemic especially in India."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This may suggest that designing a therapeutic approach against ORF6, ORF10 and E genes may have a beneficial effect in controlling COVID-19 pandemic especially in India."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Coronavirus disease 2019 (COVID-19), caused by an outbreak of the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) in Wuhan, China, has led to an unprecedented health and economic crisis worldwide [1]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Initially reported in December 2019 in the Chinese city of Wuhan, and potentially linked to a zoonosis related to a wild animal market, COVID-19 has rapidly spread globally, and the World Health Organization (WHO) declared a pandemic on March 11th 2020."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These figures make COVID-19 the biggest health emergency of the 21st century."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "COVID-19 typically manifests as an acute respiratory distress syndrome with fever, dry cough and breathing difficulties."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In any case, COVID-19 spreads at an alarming rate, and both mortality rate and severity increase with age and depend on pre-existing comorbidity, such as hypertension and diabetes, which are age-related diseases."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This defines COVID-19 as an aging-dependent disease with outcomes determined by biological age."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The input dataset for the analysis, formatted from Bojkova et al. [10], is compiled in Supplementary Table 1."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The linoleic acid metabolism pathway is linked to arachidonic acid metabolism and eicosanoids pathway, and it could therefore play a role in the inflammatory response observed in disease stages II and III in COVID-19 patients [12]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This observation suggests that these two proteins may serve as early systemic biomarkers for COVID-19 infection."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We hypothesize that dysregulation of some of the key components of the renin-angiotensin system could be related to the lung injury and worsening observed in COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "It has also been suggested that differential levels of ACE2 in the cardiac and pulmonary tissues of younger versus older adults may be at least partially responsible for the worse outcomes seen in elderly COVID-19 patients [30]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The impact of reduced ACE2 expression, together with the poorer clinical outcomes observed when comorbidities are present [31], which is also generally associated to age, makes the link between COVID-19 and aging strong."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In any case, discontinuation of ACE-Is/ARBs in hypertension patients with COVID-19 might further decrease ACE2 levels, therefore worsening disease prognosis."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In support of this notion, a recent study found that COVID-19 patients with untreated hypertension presented higher mortality than those treated with ACE-Is/ARBs [33]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Coronavirus disease 2019 (COVID-19), caused by an outbreak of the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) in Wuhan, China, has led to an unprecedented health and economic crisis worldwide."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Upregulation of inflammatory response proteins is in line with the propagation of inflammatory reaction and lung injury that is observed in advanced stages of COVID-19 patients and which worsens with age."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The present coronavirus disease 2019 (COVID‐19) is a pandemic respiratory disease caused by the novel SARS CoV‐2."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Furthermore, in order to estimate the evolutionary progression of the bat SARS CoV genome, such that it is able to adapt to a human host as a novel coronavirus causing COVID‐19, we have analyzed the complete genomes of the bat, civet, human SARS CoV, and human SARS CoV‐2."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The spike proteins were retrieved from the ",
            "NCBI",
            " database using the sequence similarity search BLAST program,",
            " with human SARS CoV‐2 spike protein as the query sequence (",
            "NCBI",
            " code: ",
            "QHD43416",
            ") from the genome (",
            "GenBank",
            " code: ",
            "MN908947.3",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 430,
                "end": 434,
                "name": "NCBI"
            },
            false,
            false,
            {
                "id": "T2",
                "type": "Repository",
                "start": 556,
                "end": 560,
                "name": "NCBI"
            },
            false,
            {
                "id": "T3",
                "type": "AccessionNumber",
                "start": 567,
                "end": 575,
                "name": "QHD43416"
            },
            false,
            {
                "id": "T4",
                "type": "Repository",
                "start": 594,
                "end": 601,
                "name": "GenBank"
            },
            false,
            {
                "id": "T5",
                "type": "AccessionNumber",
                "start": 608,
                "end": 618,
                "name": "MN908947.3"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T2",
                "end": "T3"
            },
            {
                "id": "R2",
                "bool": true,
                "head": "T4",
                "end": "T5"
            }
        ]
    },
    {
        "sen": [
            "The complete genome nucleotide sequences of SARS CoV from bats, civets, and SARS CoV and CoV‐2 from human host were obtained from ",
            "NCBI",
            " virus database (",
            "https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide",
            ") in FASTA format."
        ],
        "lab": [
            false,
            {
                "id": "T6",
                "type": "Repository",
                "start": 751,
                "end": 755,
                "name": "NCBI"
            },
            false,
            {
                "id": "T7",
                "type": "URL",
                "start": 772,
                "end": 845,
                "name": "https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide"
            },
            false
        ],
        "rel": [
            {
                "id": "R3",
                "bool": true,
                "head": "T6",
                "end": "T7"
            }
        ]
    },
    {
        "sen": [
            "The redundancy in each data set was removed using the CD‐HIT program."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In the NGPhylogeny server, we have selected FastME 2.0 program that infers phylogenies using a distance approach since it is capable of handling large data sets."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Abstract  Coronavirus disease 2019 (COVID‐19) is a pandemic infectious disease caused by novel severe acute respiratory syndrome coronavirus‐2 (SARS CoV‐2)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "2745 protein and 1702 complete genome sequences reported sequences available on May 18th 2020 were downloaded from the ",
            "COVID 19 data hub",
            "."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 119,
                "end": 136,
                "name": "COVID 19 data hub"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Sequences with the following IDs ",
            "NC_045512",
            " and ",
            "YP_009724390.1",
            " were considered as reference sequences (refseq) since they are both available at the ",
            "COVID 19 data hub",
            "."
        ],
        "lab": [
            false,
            {
                "id": "T2",
                "type": "AccessionNumber",
                "start": 171,
                "end": 180,
                "name": "NC_045512"
            },
            false,
            {
                "id": "T3",
                "type": "AccessionNumber",
                "start": 185,
                "end": 199,
                "name": "YP_009724390.1"
            },
            false,
            {
                "id": "T4",
                "type": "Dataset",
                "start": 285,
                "end": 302,
                "name": "COVID 19 data hub"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "From the ",
            "NCBI",
            " database, the primary sequence of SARS-CoV-2 spike glycoprotein (ID Sequence: ",
            "YP_009724390.1",
            ") was found."
        ],
        "lab": [
            false,
            {
                "id": "T5",
                "type": "Repository",
                "start": 313,
                "end": 317,
                "name": "NCBI"
            },
            false,
            {
                "id": "T6",
                "type": "AccessionNumber",
                "start": 396,
                "end": 410,
                "name": "YP_009724390.1"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T5",
                "end": "T6"
            }
        ]
    },
    {
        "sen": [
            "The ",
            "PDB",
            " ID: ",
            "6VYB",
            " represents the up conformation, whereas ",
            "PDB",
            " ID: ",
            "6VXX",
            " constitutes the down conformation."
        ],
        "lab": [
            false,
            {
                "id": "T7",
                "type": "Repository",
                "start": 427,
                "end": 430,
                "name": "PDB"
            },
            false,
            {
                "id": "T8",
                "type": "AccessionNumber",
                "start": 435,
                "end": 439,
                "name": "6VYB"
            },
            false,
            {
                "id": "T9",
                "type": "Repository",
                "start": 480,
                "end": 483,
                "name": "PDB"
            },
            false,
            {
                "id": "T10",
                "type": "AccessionNumber",
                "start": 488,
                "end": 492,
                "name": "6VXX"
            },
            false
        ],
        "rel": [
            {
                "id": "R2",
                "bool": true,
                "head": "T7",
                "end": "T8"
            },
            {
                "id": "R3",
                "bool": true,
                "head": "T9",
                "end": "T10"
            }
        ]
    },
    {
        "sen": [
            "In the ",
            "PDB",
            " database we searched for the structures of the MHC-I-II proteins; for the HLA-DRB1*0401 molecule, the crystal with the ",
            "PDB",
            " ID: ",
            "6BIJ",
            ", for HLA-A*2402 we used the crystal structure ",
            "PDB",
            " ID: ",
            "3W0W",
            ", and for HLA-A*0301 we used the structure ",
            "PDB",
            " ID: ",
            "2XPG",
            " whereas for the HLA-DRB1*0701 molecule, we did not find a structure in the ",
            "PDB",
            ", so we modeled the structure by homology modeling using Program Modeller 9.23 (Webb & Sali, 2016)."
        ],
        "lab": [
            false,
            {
                "id": "T11",
                "type": "Repository",
                "start": 535,
                "end": 538,
                "name": "PDB"
            },
            false,
            {
                "id": "T12",
                "type": "Repository",
                "start": 658,
                "end": 661,
                "name": "PDB"
            },
            false,
            {
                "id": "T13",
                "type": "AccessionNumber",
                "start": 666,
                "end": 670,
                "name": "6BIJ"
            },
            false,
            {
                "id": "T14",
                "type": "Repository",
                "start": 717,
                "end": 720,
                "name": "PDB"
            },
            false,
            {
                "id": "T15",
                "type": "AccessionNumber",
                "start": 725,
                "end": 729,
                "name": "3W0W"
            },
            false,
            {
                "id": "T16",
                "type": "Repository",
                "start": 772,
                "end": 775,
                "name": "PDB"
            },
            false,
            {
                "id": "T17",
                "type": "AccessionNumber",
                "start": 780,
                "end": 784,
                "name": "2XPG"
            },
            false,
            {
                "id": "T18",
                "type": "Repository",
                "start": 860,
                "end": 863,
                "name": "PDB"
            },
            false
        ],
        "rel": [
            {
                "id": "R4",
                "bool": true,
                "head": "T12",
                "end": "T13"
            },
            {
                "id": "R5",
                "bool": true,
                "head": "T14",
                "end": "T15"
            },
            {
                "id": "R6",
                "bool": true,
                "head": "T16",
                "end": "T17"
            }
        ]
    },
    {
        "sen": [
            "We employed the crystal structure ",
            "PDB",
            " ID: ",
            "3PDO",
            " as a template, with an identity of 100% for the alpha chain and an identity of 89.90% for the beta chain."
        ],
        "lab": [
            false,
            {
                "id": "T19",
                "type": "Repository",
                "start": 997,
                "end": 1000,
                "name": "PDB"
            },
            false,
            {
                "id": "T20",
                "type": "AccessionNumber",
                "start": 1005,
                "end": 1009,
                "name": "3PDO"
            },
            false
        ],
        "rel": [
            {
                "id": "R7",
                "bool": true,
                "head": "T19",
                "end": "T20"
            }
        ]
    },
    {
        "sen": [
            "The sequence ID ",
            "YP_009724390.1",
            " was analyzed through the Servers NetMHC 4.0 Server and NetMHCII 2.3 to predict immunogenic regions which could induce antibodies against the virus SARS-CoV-2."
        ],
        "lab": [
            false,
            {
                "id": "T21",
                "type": "AccessionNumber",
                "start": 1132,
                "end": 1146,
                "name": "YP_009724390.1"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition, as mentioned in the databases where the frequency of the alleles has been investigated, we found that the HLA-DRB1*0401 and HLA-A*2401 alleles are distributed in different ethnic groups, therefore these peptides could be used as a base to design new vaccines for different human races or ethnic groups, which are important because SARS-CoV-2 is not only in China but also distributed in different countries."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Abstract  The Coronavirus disease named COVID-19 is caused by the virus reported in 2019 first identified in China."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Then incorporate the desired mutation at the end of section B (40th base pair, or the 39th and 40th base pair if two changes are required)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Is airborne transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a potential means of spreading coronavirus disease 2019 (COVID-19)?",
            "In this cohort study of 128 individuals who rode 1 of 2 buses and attended a worship event in Eastern China, those who rode a bus with air recirculation and with a patient with COVID-19 had an increased risk of SARS-CoV-2 infection compared with those who rode a different bus."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Importance  Evidence of whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), can be transmitted as an aerosol (ie, airborne) has substantial public health implications."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To investigate potential transmission routes of SARS-CoV-2 infection with epidemiologic evidence from a COVID-19 outbreak."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This cohort study examined a community COVID-19 outbreak in Zhejiang province."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We also divided seats on the exposed bus into high-risk and low-risk zones according to the distance from the source patient and compared COVID-19 risks in each zone."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "On bus 2, 24 of the 68 individuals (35.3% [including the index patient]) received a diagnosis of COVID-19 after the event."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Among the other 172 individuals at the worship event, 7 (4.1%) subsequently received a COVID-19 diagnosis."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Individuals in bus 2 had a 34.3% (95% CI, 24.1%-46.3%) higher risk of getting COVID-19 compared with those in bus 1 and were 11.4 (95% CI, 5.1-25.4) times more likely to have COVID-19 compared with all other individuals attending the worship event."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Within bus 2, individuals in high-risk zones had moderately, but nonsignificantly, higher risk for COVID-19 compared with those in the low-risk zones."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In this cohort study and case investigation of a community outbreak of COVID-19 in Zhejiang province, individuals who rode a bus to a worship event with a patient with COVID-19 had a higher risk of SARS-CoV-2 infection than individuals who rode another bus to the same event."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This cohort study examines the potential for airborne spread of COVID-19 through investigation of an outbreak among bus riders in Eastern China."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Similar to its predecessors, the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) [2,3], infection with SARS-CoV-2 (officially named COVID-19 by the World Health Organization on February 11, 2020) can manifest as bronchitis, pneumonia, or a severe respiratory illness."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To generate a composite phylogenetic tree, we randomly removed sequences to create a dataset proportional to these newly isolated sequences, keeping in mind that the homologous sequences remain in the final alignment."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The evolutionary relationships of these newly sequenced Saudi MERS-CoV isolates were assessed in combination with the globally isolated sequences available in the ",
            "GenBank",
            " database (Figs. 1,2",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 722,
                "end": 729,
                "name": "GenBank"
            },
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The end of 2019 marked the beginning of the COVID-19 (Coronavirus Disease 2019) pandemic [1]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "COVID-19 is a respiratory disease caused by a novel coronavirus that has been named SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The ",
            "Global Initiative on Sharing All Influenza Data (GISAID)",
            " database [8] has provided data on variations in the WHO-recommended primer binding regions for the SARS-CoV-2 genomes [9] with the so-called Charité primers situated in the most conserved regions and the China-CDC primers in variable sites."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 244,
                "end": 300,
                "name": "Global Initiative on Sharing All Influenza Data (GISAID)"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Most of the COVID-19 cases reported in Nepal have been traced back to Nepalese migrating from India during the pandemic (Supplementary Table 1)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We analysed primer and probe binding sites in the genomes of SARS-CoV-2 deposited in the ",
            "GISAID",
            " originating from Indian labs."
        ],
        "lab": [
            false,
            {
                "id": "T2",
                "type": "Dataset",
                "start": 776,
                "end": 782,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Genomic sequence data for all Indian SARS-CoV-2 samples collected on or before 29 March 2020 were recovered from the ",
            "GISAID",
            " database on 7 May 2020."
        ],
        "lab": [
            false,
            {
                "id": "T3",
                "type": "Dataset",
                "start": 930,
                "end": 936,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We sincerely want to avoid any misinterpretations that may arise based on the content of this letter with respect to the Indian origin of COVID-19 patients in Nepal."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We would like to thank Dr. Shravan Kumar Mishra, NPHL (Nepal), for describing the more recent use of COVID-19 diagnostic kits in NPHL."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Our sincere gratitude goes to all the scientists and submitting laboratories (Supplementary Acknowledgement Table 2) involved in collection, processing and deposition of SARS-CoV-2 sequences as well as the meta-data in ",
            "GISAID",
            " without which this work could not have been done."
        ],
        "lab": [
            false,
            {
                "id": "T4",
                "type": "Dataset",
                "start": 1481,
                "end": 1487,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Most of the COVID-19 cases in Nepal are in the Southern districts of Nepal bordering India with travel histories to India.    •",
            "Very few positive cases of COVID-19 are detected in Nepal which could either be due to early national lockdown."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Whole genomes of 93 clinical samples from COVID-19 patients were analyzed to find the primer and probe binding sites."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The genome (accession no. ",
            "KP981644",
            ") is from the most virulent pantropic CCoV invading multiple canine organs (Buonavoglia et al."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "AccessionNumber",
                "start": 26,
                "end": 34,
                "name": "KP981644"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The green arrow points to CCoV (accession ",
            "KC175339",
            " in the phylogeny) that had been propagated extensively in cell culture before sequencing."
        ],
        "lab": [
            false,
            {
                "id": "T2",
                "type": "AccessionNumber",
                "start": 171,
                "end": 179,
                "name": "KC175339"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "There are two genomes sequenced for CRCoV (accession nos. ",
            "JX860640",
            " and ",
            "KX432213",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T3",
                "type": "AccessionNumber",
                "start": 328,
                "end": 336,
                "name": "JX860640"
            },
            false,
            {
                "id": "T4",
                "type": "AccessionNumber",
                "start": 341,
                "end": 349,
                "name": "KX432213"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "3, genome accession ",
            "KC175339",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T5",
                "type": "AccessionNumber",
                "start": 372,
                "end": 380,
                "name": "KC175339"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The interpretation is further corroborated by a recent report that a high proportion of COVID-19 patients also suffer from digestive discomfort (Pan et al. 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In a comprehensive study of the first 12 COVID-19 patients in the United States (Midgley and The COVID-19 Investigation Team, 2020), one patient reported diarrhea as the initial symptom before developing fever and cough (Midgley and The COVID-19 Investigation Team, 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Stool samples from 7 out of 10 patients tested positive for SARS-CoV-2, including 3 patients with diarrhea (Midgley and The COVID-19 Investigation Team, 2020), corroborating a previous report of SARS-CoV-2 detection in stool (Holshue et al. 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In particular, live SARS-CoV-2 virus was isolated from stool of a COVID-19 patient (Zhang et al. 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Nine SARS-CoV-2-like genomes have recently been isolated and sequenced from pangolin and deposited in ",
            "GISAID",
            " database (",
            "gisaid.org",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T6",
                "type": "Dataset",
                "start": 1273,
                "end": 1279,
                "name": "GISAID"
            },
            false,
            {
                "id": "T7",
                "type": "URL",
                "start": 1290,
                "end": 1300,
                "name": "gisaid.org"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T6",
                "end": "T7"
            }
        ]
    },
    {
        "sen": [
            "The one with the highest sequence coverage (",
            "GISAID",
            " ID: ",
            "EPI_ISL_410721",
            ") has an ICpG value of 0.3929, close to the extreme low end of ICpG values observed among available SARS-CoV-2 genomes."
        ],
        "lab": [
            false,
            {
                "id": "T8",
                "type": "Dataset",
                "start": 1347,
                "end": 1353,
                "name": "GISAID"
            },
            false,
            {
                "id": "T9",
                "type": "AccessionNumber",
                "start": 1358,
                "end": 1372,
                "name": "EPI_ISL_410721"
            },
            false
        ],
        "rel": [
            {
                "id": "R2",
                "bool": true,
                "head": "T8",
                "end": "T9"
            }
        ]
    },
    {
        "sen": [
            "At present, the world is suffering from a pandemic of SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19) and has a global mortality rate that remains to be determined (Wu et al., 2020, Zhu et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "More severe cases of COVID-19 develop acute respiratory distress syndrome and acute lung injury, leading to morbidity and mortality caused by damage to the alveolar lumen leading to inflammation and pneumonia (Wolfel et al., 2020, Xu et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The current pandemic of COVID-19 is an acute and rapidly developing global health crisis."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To better understand the molecular basis of the disease, we sought to characterize the transcriptional response to infection in a variety of model systems, including in vitro tissue culture, ex vivo infection of primary cells, and in vivo samples derived from COVID-19 patients and animals."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Additional research in this area will be required to ascertain whether this is a contributing factor toward the development of COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To this end, we first compared post-mortem lung samples from COVID-19-positive patients with biopsied healthy lung tissue from uninfected individuals."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These two cohorts tested positive for SARS-CoV-2 by nasopharyngeal swabs or were admitted to the hospital for non-COVID-19-related respiratory issues (n = 24 for each group)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Moreover, analyses of cytokines and chemokines quantified in individual serum samples revealed enhancement of generalized inflammation among COVID-19 patients, marked by a significant increase in circulating IL-6, IL1RA, CCL2, CCL8 CXCL2, CXCL8, CXCL9, and CXCL16 levels (Figure 4C)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Significant elevation of CXCL9 and CXCL16 (chemoattractants of T or natural killer (NK) cells, respectively), CCL8 and CCL2 (which recruit monocytes and/or macrophages), and CXCL8 (a classic neutrophil chemoattractant) suggest that the presence of these cells may be a primary driver of the signature pathology observed in COVID-19 patients (Proudfoot, 2002)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Although this sample size is not necessarily representative of the whole population of infected COVID-19 patients, our data are consistent with what we observe using our other model systems."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In the present study, we focus on defining the host response to SARS-CoV-2 and other human respiratory viruses in cell lines, primary cell cultures, ferrets, and COVID-19 patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These dynamics are also likely to contribute to development of COVID-19 during the course of infection (Wolfel et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A recent study analyzing severe versus mild cases of COVID-19 showed that peripherally derived macrophages predominated in the lungs of severe cases (Liao et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition, our data suggest that neutrophils could also contribute to the disease observed in COVID-19 patients, as demonstrated by CXCL2 and CXCL8 induction."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This is consistent with data showing elevated circulating neutrophil levels among COVID-19 patients (Chen et al., 2020, Qin et al., 2020), which may have prognostic value for identifying individuals at risk for developing severe disease."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "It is also noteworthy that two of the cytokines uniquely elevated in response to SARS-CoV-2 are IL-6 and IL1RA, suggesting that there might be a parallel between COVID-19 and cytokine release syndrome (CRS), a complication commonly seen following CAR T-cell treatment (Giavridis et al., 2018)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Should this be true, drugs such as tocilizumab and anakinra may prove to be beneficial for treatment of COVID-19 (Norelli et al., 2018)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "SARS-related coronavirus 2 (SARS-CoV-2), Isolate USA-WA1/2020 (NR-52281) was deposited by the Center for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "All RNA-Seq data performed in this paper can be found on the ",
            "NCBI",
            " ",
            "Gene Expression Omnibus (GEO)",
            " under accession number ",
            "GSE147507",
            "."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 3694,
                "end": 3698,
                "name": "NCBI"
            },
            false,
            {
                "id": "T2",
                "type": "Repository",
                "start": 3699,
                "end": 3728,
                "name": "Gene Expression Omnibus (GEO)"
            },
            false,
            {
                "id": "T3",
                "type": "AccessionNumber",
                "start": 3752,
                "end": 3761,
                "name": "GSE147507"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T2",
                "end": "T3"
            }
        ]
    },
    {
        "sen": [
            "Cell and animal models of SARS-CoV-2 infection, in addition to transcriptional and serum profiling of COVID-19 patients, consistently revealed a unique and inappropriate inflammatory response."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We propose that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine production are the defining and driving features of COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Low innate antiviral defenses and high pro-inflammatory cues contribute to COVID-19      In comparison to other respiratory viruses, SARS-CoV-2 infection drives a lower antiviral transcriptional response that is marked by low IFN-I and IFN-III levels and elevated chemokine expression, which could explain the pro-inflammatory disease state associated with COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Early reports from these institutions showed that severe kidney disease is a hallmark of severe COVID disease."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Their finding could offer confirmatory evidence that direct renal infection occurs in the setting of AKI in COVID‐19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The authors found that collapsing glomerulopathy in black patients with COVID‐19 was associated with high‐risk APOL1 variants."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Given this entity's resemblance with HIV‐associated nephropathy, the authors proposed the term COVID‐19‐associated nephropathy to describe the condition."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "COVID‐19 is recent and, therefore, case records are common and valuable."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These states‐of‐affairs confront nephrologists and intensivists in the COVID‐19 pandemic, in less fortunate clinical settings, all the more so."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Since COVID‐19 has afflicted many patients, AKI patient series have been collected."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "They found that the available limited published data to indicate that severe AKI in patients with COVID‐19 is an ominous clinical predictor and is associated with high mortality (no surprise here)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "They were at least able to determine an incidence AKI rate of 10% in COVID‐19 patients, albeit the range in their series was huge (so as not to be helpful)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We cannot determine a specific form of COVID‐19 AKI or chronic nephropathy."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Her physicians considered the diagnosis of COVID‐10 disease that was confirmed."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Cassol et al have recently counselled for caution in interpreting these findings (Preprint https://doi.org/10.34067/KID.0002692020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In contrast to the AIDS epidemic (largely ignored for decades), SARS‐Co‐V2 received immediate attention, in terms of genomic sequencing, assay development, sharing of diagnostic data, vaccine development and other international cooperation."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We, (Covid‐19 Charité investigators) are conducting a prospective investigation that includes incorporation of recent “biomarkers” for AKI in a patient population likely to need them."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Although SARS-CoV-2 infection of lung epithelium is a critical driver of disease, extrapulmonary manifestations of coronavirus disease 2019 (COVID-19) infection (Gupta et al., 2020) have been associated with direct viral damage of tissues that carry the ACE2 receptor, such as intestinal enterocytes and renal tissue (Monteil et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Deciphering the regulation of the ACE2 gene in SARS-CoV-2 target cells is a step forward in linking ACE2 levels with viral damage and COVID-19 pathology."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Although a body of work has focused on the pathology of COVID-19 during pregnancy (Khalil et al., 2020), the extent to which hormones control ACE2 expression during pregnancy and lactation, and possibly the susceptibility of cells to SARS-CoV-2 infection, has not been investigated."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Expression of the ACE2 gene in type II pneumocytes is activated by IFNs (Ziegler et al., 2020), opening the possibility that the cytokine storm in COVID-19 patients, and peptide hormones in general, might lead to increased levels of ACE2 in a range of putative SARS-CoV-2 target tissues."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To directly link the activation of the intronic enhancer to increased Ace2 expression, we analyzed ChIP-seq datasets throughout pregnancy, lactation, and involution (Figure 3",
            ")."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Our findings built a framework needed to assess and understand the contributions of a range of cytokines faced under various physiological conditions in extrapulmonary manifestations of COVID-19 (Gupta et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Although SARS-CoV-2 has been detected in breast milk in at least seven studies and our research has demonstrated that its receptor ACE2 is present in mammary tissue and highly induced during lactation, the impact of these findings on COVID-19 requires further investigation."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "They are used to suppress cytokine storms induced by the pan-JAK/STAT pathway, and inflammation in COVID-19 patients treated with the JAK1/2 inhibitor ruxolitinib is reduced (La Rosée et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Similarly, baricitinib, which inhibits the proinflammatory signal of several cytokines by suppressing JAK1/JAK2, has a beneficial impact in COVID-19 patients (Cantini et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "By including steroid hormones and males and females of different ages in future studies, insight into the sex differences seen in COVID-19 morbidity and mortality (Galbadage et al., 2020) might emerge."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The world is currently faced with a pandemic of novel coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has no preventative vaccine or proven pharmacologic treatment."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "It is predicted that the development of a safe and effective vaccine to prevent COVID-19 will take 12 to 18 months, by which time many millions of people may have been infected."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Because coronaviruses causing COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS) are able to spontaneously transfer to humans from diverse animal hosts that act as viral reservoirs, there is a pressing need to develop methods to broadly combat other coronaviruses that may emerge in the future (Li et al., 2005, Mohd et al., 2016, Shi and Hu, 2008)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The novel coronavirus causing COVID-19 belongs to a family of positive-sense RNA viruses, which typically infect the upper and lower respiratory tracts and cause disease by direct cytotoxic effects and the induction of host cytokine-mediated inflammation (Liu et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We argue that this approach, in which the lentivirus-derived RNA serves as a PAC-MAN target prior to lentivirus integration into DNA, mimics the crRNA targeting conditions that would apply for natural COVID-19 infection."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In the past two decades, multiple variants of coronavirus, including those causing COVID-19, SARS, and MERS, emerged from animal reservoirs and infected humans, each time causing a significant number of fatalities (Li et al., 2005, Mohd et al., 2016, Shi and Hu, 2008)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We found that just two crRNAs could target ∼50% of coronavirus genomes, including those causing COVID-19, SARS, and MERS; six crRNAs were able to target ∼91% of coronavirus genomes; and 22 crRNAs covered all sequenced coronaviruses with no mismatches (Figure 5B; Table S4)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Beta coronaviruses, the genus of viruses causing COVID-19, SARS, and MERS, were mainly covered by three crRNAs (crRNA 1–3), while the other genera were covered by crRNA 1–3 in addition to three other crRNAs."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To verify whether crRNA-N18f can target all L and S strains, we retrieved a set of 1,087 recently sequenced SARS-CoV-2 sequences from ",
            "Global Initiative on Sharing All Influenza Data (GISAID)",
            "."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 2193,
                "end": 2249,
                "name": "Global Initiative on Sharing All Influenza Data (GISAID)"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "It is important to note that PAC-MAN is currently a proof-of-concept antiviral strategy for robustly and broadly targeting conserved viral sequences with Cas13, and multiple important steps are required before it can be tested in clinical trials to possibly treat COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These steps, including clinical trials, will likely take years; while PAC-MAN will not be able to stem the current rising tide of COVID-19 cases and related deaths, there is potential for it to be used against future viral threats."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Forward and reverse oligos for each spacer (IDT) were annealed and inserted into backbone using T4 DNA Ligase (NEB)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Currently, nucleic-acid based tests have been widely used as the reference method for the diagnosis of COVID-19.[7]",
            "The pandemic of COVID-19 was first discovered by metagenomic next-generation sequencing (mNGS) in which the novel virus was found to be a new pathogenic member of the betacoronavirus genus but shared only about 79% in genetic similarity with SARS-CoV.[8, 9]",
            "A tool kit of rapid diagnostics faster than typical RT-PCR is in great demand to circumvent the bottlenecks in assay turnaround time and reagent supply for COVID-19 testing."
        ],
        "lab": [
            false,
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Among the 61 suspected COVID-19 specimens, we were able to confirm 52 cases with read numbers mapping to the novel virus across 6 orders of magnitudes (median read of 1,484, from 2 to 19,016,501)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Among these, the set that targeted Orf1ab showed the best overall performance of sensitivity and specificity, and therefore, was used to develop CRISPR-COVID in this study for further evaluation (S2A, S2B and S2C Fig)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "As shown in Fig 2B, CRISPR-COVID consistently detected 7.5 copies/reaction of SARS-CoV-2 in all 10 replicates, 2.5 copies/reaction in 6 out of 10, and 1.25 copies/reaction in 2 out of 10 runs."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These data indicate that CRISPR-COVID had a near single-copy sensitivity."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To confirm its specificity, we tested CRISPR-COVID with DNA from human cells as well as a panel of microbes including i) bacteria commonly found in respiratory infections: S. pneumonia, H. influenza, M. pneumonia, C. pneumonia, B. pertusiss; ii) human Coronaviruses: HCoV-OC43, HCoV-NL63, HCoV-HKU1, HCoV-229E; iii) other viruses commonly found in respiratory infections: Adenovirus Type-3, H. Influenza B (Victoria), H influenza A (H3N2), HPIV-1, RSV-A; and iii) other bacteria: S. mitis, S. pyogenes, S. aureus, E. coli, E. facecaiis."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Altogether, these analytical assessments suggest CRISPR-COVID as a promising molecular assay for SARS-CoV-2 detection with great sensitivity and specificity."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Upon completion of the analytical assessment, we further evaluated the diagnostic potential of CRIPSR-COVID in clinical specimens."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A total of 114 RNA samples from clinical respiratory samples were included in the evaluation, which consisted of 61 suspected COVID-19 cases (among which 52 confirmed and 9 ruled-out by mNGS), 17 SARS-CoV-2-/hCoV+ cases and 36 samples from healthy subjects (Fig 3A)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "When conducting the CRISPR-COVID assay, a positive control (PC) DNA and a no-template control (NC) were included in parallel for each run."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "CRISPR-COVID demonstrated a sensitivity of 100% by detecting all 52 COVID-19 cases."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "No false positives were found in all 62 negative cases, including all the hCoV-infected ones (Fig 3B), suggesting promising clinical sensitivity and specificity of CRISPR-COVID."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To further evaluate assay compatibility, the primer and gRNA sequences used in CRISPR-COVID were aligned to 2,439 SARS-CoV-2 genomes obtained from public databases."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "As these genomes covered wide ranges of collection times (from 2019/12/24 to 2020/05/06) and geographic locations (over 20 countries including China, United States and France etc.), our results suggest the general applicability of our assay for COVID-19 diagnosis."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Using mNGS and the PCR as the reference, CRISPR-COVID had a specificity of 100% in our study."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "PCR-COVID was able to detect the virus in 90.4% (47/52) of the positive cases, with Ct’s ranging from 28.8 to 40.4 and a median Ct of 35.8."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "It’s worth noting that the 5 false negative samples by PCR-COVID had a median mNGS read number of 550, which was much lower than that of the other positive samples at 2,381 reads, suggesting a lower titer of the virus in these samples."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "CRISPR showed a greater sensitivity by detecting all 52 COVID-19 cases (100%), with FC values ranging from 5.0 to 66.3 and a median FC of 22.8 (Fig 3C)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "When the reaction turn-around time (TAT) is compared, the CRISPR-COVID reaction requires only 40 minutes, which is the least among the three and includes 30 minutes of DNA amplification and 10 minutes of Cas reaction."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "PCR-COVID requires about 1.5 hours for a completion run of the PCR program."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "As showed in Fig 4, CRISPR-COVID presented a significant advantage in effective TAT over PCR and mNGS."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Recent progresses in molecular diagnostic technologies, especially mNGS, allowed rapid, initial identification of this novel pathogenic agent at the beginning of the current COVID-19 pandemic.[8]",
            "However, the sudden outbreak of COVID-19 created a dramatic burden not only on the society, but also on public health."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The surging demand for rapid screening and identification of COVID-19 posts a great challenge on the diagnostics.[21]",
            "An RT-PCR assay for COVID-19 is faster and more affordable."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "As we demonstrated in this study, CRISPR-COVID was able to deliver comparable sensitivity and specificity as mNGS within as short as 40 minutes."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "At research scale, the material costs of a CRISPR-COVID test runs at less than $3.5, which could be dramatically reduced at production scale to below $0.7[23], suggesting CRISPR-COVID as a competitive alternative not only technologically but also financially."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "RT-PCR assays for COVID-19 were performed using a clinically validated kit approved by the Chinese National Medical Products Administration (Liferiver, Shanghai, China) on a ABI-7500 Real-Time PCR System (Thermo Fisher Scientific, Carlsbad, CA) according to the instructions, with Ct values below 40 considered positive."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Clean reads were aligned against the reference microbial databases including archaea, bacteria, fungi, protozoa, and viruses."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The CRISPR-COVID test combines an Reverse-transcription Recombinase Polymerase Amplification (RT-RPA) step and a following T7 transcription and Cas13 detection step as described previously. [17]",
            "In this study, we developed an isothermal, CRISPR-based diagnostic for COVID-19 with near single-copy sensitivity."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The recently discovered betacoronavirus severe acute respiratory syndrome (SARS)-CoV-2 has caused an outbreak of Coronavirus Disease 2019 (COVID-19) that rapidly developed into a global pandemic."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The surging demand for rapid screening and identification of COVID-19 posts great diagnostic challenges."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Here, we harnessed the unique collateral activity of programmable CRISPR/Cas13a to develop CRISPR-COVID, a rapid and sensitive diagnostic for SARS-CoV-2 infection, and compared it to sequencing-based metagenomic and RT-PCR-based assays in a clinical cohort."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "CRISPR-COVID demonstrated a sensitivity level of near single copy and was highly specific without cross reacting to related pathogens."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "CRISPR-COVID takes only 40 mins and requires no sophiscated thermo-cyclers, providing a valuable alternative to the conventional RT–PCR assay to circumvent the bottlenecks in assay turnaround time, equipment and reagent supplies for COVID-19 testing."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Without effective management, COVID-19 could be catastrophic in Africa, exacerbated by high infectious and non-infectious disease burdens, poor healthcare access and limited health resources."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "4 5 African COVID-19 disease profiles may also differ given unique regional environmental challenges, population structure and genetic make-up, and potential proliferation of specific virus strains, limiting transferability of research findings from other continents."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In this novel COVID-19 pandemic, IRBs have no recourse to historical evidence, and require support in both decision-making challenges and a greatly increased workload."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Previous pandemic experience has informed recommendations for strengthening and expediting IRB processes,11 12 members of the scientific community can be co-opted to assess proposals for scientific integrity, and government offices and scientific organisations can provide guidelines for acceptable practices (eg, African Academy of Sciences COVID-19 research ethics, https://www.aasciences.africa/)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Maximising benefit to patient populations is essential for ethical COVID-19 research in Africa, given limited healthcare capacity."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Non-traditional engagement of community members provided in local languages by local fieldworkers must accommodate potentially limited resources available to participants and researchers, for example, using call-back short message services (SMS), toll-free numbers for information, printed materials and free-data websites combining information about COVID-19 public health measures and proposed studies."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Locally relevant COVID-19 health promotion information and links to local psycho-social support should also be provided."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Existing datasets may be retrospectively analysed, or used as control data for COVID-19 studies where ethics approval is in place."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Such data can be anonymised, de-identified, perturbed and aggregated to be useful comparison datasets without compromising participants; or new consent can be sought for repurposing existing data."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The sequences used for analysis were downloaded from ",
            "NCBI",
            " (",
            "http://www.ncbi.nlm.nih.gov/",
            ") and ",
            "GISAID",
            " (",
            "http://www.gisaid.org",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 53,
                "end": 57,
                "name": "NCBI"
            },
            false,
            {
                "id": "T2",
                "type": "URL",
                "start": 59,
                "end": 87,
                "name": "http://www.ncbi.nlm.nih.gov/"
            },
            false,
            {
                "id": "T3",
                "type": "Dataset",
                "start": 93,
                "end": 99,
                "name": "GISAID"
            },
            false,
            {
                "id": "T4",
                "type": "URL",
                "start": 101,
                "end": 122,
                "name": "http://www.gisaid.org"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T1",
                "end": "T2"
            },
            {
                "id": "R2",
                "bool": true,
                "head": "T3",
                "end": "T4"
            }
        ]
    },
    {
        "sen": [
            "Next-generation sequencing of BetaCoV/Korea/SNU01/2020 (",
            "GenBank",
            " accession no. ",
            "MT039890",
            ") revealed 9 mutations compared to the ",
            "NC_045512",
            " reference genome isolated from Wuhan (Table 1)."
        ],
        "lab": [
            false,
            {
                "id": "T5",
                "type": "Repository",
                "start": 181,
                "end": 188,
                "name": "GenBank"
            },
            false,
            {
                "id": "T6",
                "type": "AccessionNumber",
                "start": 203,
                "end": 211,
                "name": "MT039890"
            },
            false,
            {
                "id": "T7",
                "type": "AccessionNumber",
                "start": 250,
                "end": 259,
                "name": "NC_045512"
            },
            false
        ],
        "rel": [
            {
                "id": "R3",
                "bool": true,
                "head": "T5",
                "end": "T6"
            },
            {
                "id": "R4",
                "bool": true,
                "head": "T5",
                "end": "T7"
            }
        ]
    },
    {
        "sen": [
            "The emergence of SARS-coronavirus-2 (SARS-CoV-2), which causes coronavirus-mediated disease 2019, or COVID-19, has now spread pandemically, resulting in a serious global health crisis."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The SARS-CoV-2 genome sequences from England (hCoV-19/England/20136087804/2020|",
            "EPI_ISL_420910",
            ", no treatment) and Turkey (hCoV-19/Turkey/GLAB-CoV008/2020) were obtained from the China National Bioinformatics Center, ",
            "GISAID",
            " database [23] (",
            "https://www.gisaid.org",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "AccessionNumber",
                "start": 264,
                "end": 278,
                "name": "EPI_ISL_420910"
            },
            false,
            {
                "id": "T2",
                "type": "Dataset",
                "start": 400,
                "end": 406,
                "name": "GISAID"
            },
            false,
            {
                "id": "T3",
                "type": "URL",
                "start": 422,
                "end": 444,
                "name": "https://www.gisaid.org"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T2",
                "end": "T1"
            },
            {
                "id": "R2",
                "bool": true,
                "head": "T2",
                "end": "T3"
            }
        ]
    },
    {
        "sen": [
            "DianaTools miRPath V3 were then used to create heat maps for pathways affected by selected miRs, focusing on the microT-CDS version 5.0 database."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The data have been deposited with links to BioProject accession number ",
            "PRJNA615032",
            " in the ",
            "NCBI",
            " BioProject database (",
            "https://www.ncbi.nlm.nih.gov/bioproject/",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T4",
                "type": "AccessionNumber",
                "start": 664,
                "end": 675,
                "name": "PRJNA615032"
            },
            false,
            {
                "id": "T5",
                "type": "Repository",
                "start": 683,
                "end": 687,
                "name": "NCBI"
            },
            false,
            {
                "id": "T6",
                "type": "URL",
                "start": 709,
                "end": 749,
                "name": "https://www.ncbi.nlm.nih.gov/bioproject/"
            },
            false
        ],
        "rel": [
            {
                "id": "R3",
                "bool": true,
                "head": "T5",
                "end": "T4"
            },
            {
                "id": "R4",
                "bool": true,
                "head": "T5",
                "end": "T6"
            }
        ]
    },
    {
        "sen": [
            "Several database sources were referenced for enrichment analysis, including ",
            "Interpro",
            " [32], ",
            "NCBI",
            " [33], ",
            "MSigDB",
            " [34,35], ",
            "REACTOME",
            " [36], and ",
            "WikiPathways",
            " [37]."
        ],
        "lab": [
            false,
            {
                "id": "T7",
                "type": "Repository",
                "start": 828,
                "end": 836,
                "name": "Interpro"
            },
            false,
            {
                "id": "T8",
                "type": "Repository",
                "start": 843,
                "end": 847,
                "name": "NCBI"
            },
            false,
            {
                "id": "T9",
                "type": "Repository",
                "start": 854,
                "end": 860,
                "name": "MSigDB"
            },
            false,
            {
                "id": "T10",
                "type": "Repository",
                "start": 870,
                "end": 878,
                "name": "REACTOME"
            },
            false,
            {
                "id": "T11",
                "type": "Repository",
                "start": 889,
                "end": 901,
                "name": "WikiPathways"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The ",
            "miRBase",
            " online database holds 2565 miR sequences and from these we identified regions of the SARS-CoV-2 viral genome, which showed high similarity to human miRs."
        ],
        "lab": [
            false,
            {
                "id": "T12",
                "type": "Repository",
                "start": 912,
                "end": 919,
                "name": "miRBase"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The selected intersected pathways were analyzed as significant targets as p value 0.05 with threshold value 0.8 and Fisher’s Exact Test (hypergeometric distribution) calculations by miRPath version 3.0 in the microT-CDS database."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Using the ",
            "GISAID",
            " database, we analysed a sample of viral genomic sequences from several geographical areas for mutations in the potential miR sequences (n = 28–133)."
        ],
        "lab": [
            false,
            {
                "id": "T13",
                "type": "Dataset",
                "start": 1314,
                "end": 1320,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition, miR-8066 is found to be associated with one of the critical clinical problems of COVID-19, the cytokine storm, owing to its potential effect on the cytokine-cytokine receptor pathway."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Briefly, the downregulation of host cell responses’ related pathway members such as SRP-dependent co-translational protein targeting to membrane, L13a-mediated translational silencing of ceruloplasmin expression antigen processing, ribosomal organization, and the ERAD pathway, were observed in COVID-19-positive lung biopsy specimens."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "miR-5197-3p was identified as the most effective miR to interact with the guide RNA of SARS-CoV, MERS-CoV and COVID-19 [49]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "According to the Harvard and MD Anderson databases, miR-5197 shows significant differences between Caucasians and Chinese populations (data gained from a Han Chinese cohort from Nanjing, China) [50]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Because of its potential presence in SARS-CoV-2-mediated cellular responses, we have analysed data from the lung tissue biopsy database (",
            "PRJNA615032",
            " Bioproject) to understand its function."
        ],
        "lab": [
            false,
            {
                "id": "T14",
                "type": "AccessionNumber",
                "start": 2465,
                "end": 2476,
                "name": "PRJNA615032"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Opioids have furthermore been shown to enhance simian acquired immunodeficiency syndrome (SAIDS) in rhesus monkeys [68], while reduced clearance of pulmonary influenza virus infection was observed in morphine-treated Lewis rats [69]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In AIDS, malabsorption of vitamin 12 has been related to gastric secretory failure, including chronic diarrhoea, due to advanced HIV infection [87,88]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Also, vitamin B3 was found to be highly effective to help lung tissue damage repair [92] and it was suggested to be given to COVID-19 patients as soon as the CT lung abnormalities were detected [93]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Sudden cardiac death is a major problem amongst the unexplained deaths in COVID-19, and it has been identified that many of those patients suffered from primary myocardial fibrosis (PMF), without any known aetiology."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Recently, higher expression of miR-1468-3p was identified as a disease-associated and age-dependent cardiac biomarker, as it promotes cardiac fibrosis and cell senescence, although no difference was noted in the mature form of miR-1468 between healthy and COVID-19-diseased cardiac tissue [101]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In our study, analysis of several SARS-CoV-19 genomes, which were isolated from different geographical regions, shows significant similarity scores with human miRs, which target a subset of genes related to pathways affecting virus pathogenicity and host responses observed in COVID-19 patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In our current study we identified that seven completely complementary miRNAs of COVID-19 (cc-miRc) prevent viral replication and protein translation processes."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a member of the betacoronavirus family, which causes COVID-19 disease."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Based on our reported findings, miRNAs may constitute potential and effective therapeutic approaches in COVID-19 and its pathological consequences."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition to the need for virus detection, evaluation of individual serological response [1], and biological analytical tools to manage COVID-19 on a population level, there is an urgent need to obtain objective information to identify at-risk individuals and to understand the marked variability in the severity of the disease in general, as well as in given populations."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Thus, in this context, here we develop two complementary themes: (i) a more thorough examination of the membrane shedding of angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 cellular target, and its potential repercussion on virus propagation; and (ii) a description of the interindividual variability of the genes (SNPs) involved in ACE2 processing and their potential impact on the risk of contracting COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Chen et al. recently examined a large ",
            "Genotype–Tissue Expression (GTEx)",
            " database and investigated the expression of ACE2 in different human tissues [3]."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 833,
                "end": 866,
                "name": "Genotype–Tissue Expression (GTEx)"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Globally, at a population level, there was a negative correlation between ACE2 expression and COVID-19 severity."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Cao et al. [5] compiled a database analysis of all 1700 variants in the region of the ACE2 gene located on the X chromosome."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "It is still debatable whether these differences should be taken into consideration in epidemiological studies on COVID-19 covering ethnic associations with disease occurrence [6]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This relationship concurs well with the study by Chen et al. pointing towards a negative correlation between ACE2 expression and COVID-19 severity [3]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A similar supervised genetic approach to COVID-19 risk assessment could complement the current unsupervised GWAS investigations, which require large population studies exploring the whole patient genome for DNA variations in an attempt to explain interindividual differences in COVID-19 severity [e.g., the Howard Hughes Medical Institute (HHMI) genetic projecti and the COVID-19 Human Genetic Effort [2])."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Ideally, in a final step, a multifactorial predictive index could be established incorporating SNP analysis and other, more established, risk factors."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Based on a broad public database compilation, we support the hypothesis that germinal polymorphisms may regulate the expression of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cellular target itself and proteases controlling the process of its shedding or, conversely, its internalization."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Consequently, a genetic influence on individual susceptibility to coronavirus disease 2019 (COVID-19) infection is strongly suspected."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In late December 2019 in Wuhan city (China), a new coronavirus called SARS-CoV-2 (initially nCoV-2019) caused the outbreak of a respiratory disease known as the infectious disease due to the new coronavirus (COVID-19) (Zhou et al., 2020; Zhu et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In Colombia, the first case of COVID-19 was identified on March 6, 2020, shortly before the World Health Organization (WHO) declared COVID-19 as a pandemic after it had spread in 114 countries in all continents and having claimed the lives of 4291 people (WHO, 2020a)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The first case of COVID-19 in Colombia was imported from Italy, a country that had the most alarming epidemic peak in Europe at that time."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Shortly afterwards, cases of COVID-19 were diagnosed in travelers from other origins, as well as in multiple of their contacts."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "After the publication of the complete SARS-CoV-2 genome in genomic data repositories such as ",
            "NCBI",
            " (",
            "MN908947.3",
            ") and the ",
            "Global Initiative on Sharing All Influenza Data (GISAID)",
            " in mid-January 2020, health agencies and researchers from different countries quickly developed SARS-CoV-2 screening tests based on real-time RT-PCR (rRT-PCR) that amplify different SARS-CoV-2 gene regions."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 886,
                "end": 890,
                "name": "NCBI"
            },
            false,
            {
                "id": "T2",
                "type": "AccessionNumber",
                "start": 892,
                "end": 902,
                "name": "MN908947.3"
            },
            false,
            {
                "id": "T3",
                "type": "Dataset",
                "start": 912,
                "end": 968,
                "name": "Global Initiative on Sharing All Influenza Data (GISAID)"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T1",
                "end": "T2"
            }
        ]
    },
    {
        "sen": [
            "A total of 39 primer and probe sequences from the main in-house rRT-PCR protocols for SARS-CoV-2 detection published at WHO website were aligned to the reference sequence derived from the first confirmed case at Wuhan, Hubei province, China, and named Wuhan-1 strain (",
            "GenBank",
            " Accession Number: ",
            "NC_045512.2",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T4",
                "type": "Repository",
                "start": 1444,
                "end": 1451,
                "name": "GenBank"
            },
            false,
            {
                "id": "T5",
                "type": "AccessionNumber",
                "start": 1470,
                "end": 1481,
                "name": "NC_045512.2"
            },
            false
        ],
        "rel": [
            {
                "id": "R2",
                "bool": true,
                "head": "T4",
                "end": "T5"
            }
        ]
    },
    {
        "sen": [
            "The Corman-Berlin (2020) RdRP SARSr-F2 (Corman et al., 2020) (Fig. 3) region was variable in one Colombian SARS-CoV-2 sequence from the department of Valle del Cauca (ID: 79943), involving a critical site at the 3′ pentamer."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The Zhu 2020 CDC-China Set I Probe(ORF1ab) (Zhu et al., 2020) (Fig. 4) was found to be almost completely complementary with the Colombian SARS-CoV-2 sequences, except for a viral sequence obtained from a human case in the department of Antioquia (ID: 79253), bearing a single substitution at the seventh probe position, without considerable effect on the thermodynamic features for probe-target hybridization (Table S1)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The primers and probes sets proposed by Pasteur 2020 (France)nCoV IP2 (Fig. S1), Hong Kong (2020) HKU-ORF1b-nsp14 (Fig. S2), Corman Berlin(2020) E Sarbeco (Fig. S3), CDC 2020(USA) 2019-nCoV N1 (Fig. S4), DMC-MH 2020(Thailand)WH-NIC N (Fig. S4), CDC 2020(USA) 2019-nCoV N3 (Fig. S5), Corman Berlin(2020) N Sarbeco (Fig. S5), Nao 2020(Japan)NIID 2019-nCOV N (Fig. S6) and CDC 2020(USA) 2019-nCoV N2 (Fig. S6) showed correspondence with the reference sequence and with all the accumulated genetic variability in available sequences of Colombian strains of SARS-CoV-2."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "One of the primers (Nao 2020(Japan)NIID 2019-nCOV N F2) had the 3′ end aligned with the first codon position of the codon CUA which encodes for alanine."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "NGS has also enabled pathogen discovery in a timely manner compared to traditional methods, being essential to the virus taxonomic classification during the beginnings of COVID-19 pandemics (Zhou et al., 2020; Zhu et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "By the time of this report, more than 31.000 sequences have been made available on ",
            "GISAID",
            " by researchers across the globe; in line with the “Common primer check for high-quality genomes 2020-05-22” analysis from this database (BII/GIS, 2020), the Zhu 2020 CDC-China Set II (N) showed the higher percent of genomes with mutation in both, the entire -and the 3′ end primer region, which can affect the sensitivity of this protocol given the genetic variability present in the country."
        ],
        "lab": [
            false,
            {
                "id": "T6",
                "type": "Dataset",
                "start": 3160,
                "end": 3166,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Detection of SARS-CoV-2 viral RNA using nucleic acid amplification techniques such as rRT-PCR continues to be the gold standard for the diagnosis of COVID-19 (WHO, 2020d)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The COVID-19 pandemic caused by SARS-CoV-2 is a public health problem unprecedented in the recent history of humanity."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Complete SARS-CoV-2 genomes were obtained from 30 COVID-19 cases, representative of the current epidemiology in the country."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Genetic variability was detected in Colombian SARS-CoV-2 sequences in some of the primer/probe regions for in-house rRT-PCR diagnostic tests available at WHO COVID-19 technical guidelines; its impact on the performance and rates of false-negative results should be experimentally evaluated."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Highlights     •  Colombian SARS-CoV-2 sequences displayed genetic variability in some target regions used for COVID-19 diagnosis.",
            "•  Genomic data of circulating SARS-CoV-2 allow the refinement of molecular protocols for COVID-19 diagnosis"
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Since its first identification as a human pathogen in the Wuhan province of China in December 2019, the SARS‐CoV‐2 virus, which causes COVID‐19, has become a global pandemic with immense medical and socio‐economic costs."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "It is comforting, however, that previous data from several randomised, double‐blind, placebo‐controlled trials indicate that ALN‐RSV01 (a siRNA‐based drug) is safe to use and effective against respiratory syncytial virus infection."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            ", ",
            " Taken together, siRNA‐based therapeutics might be considered as an effective strategy to treat of COVID‐19."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Potential effects of siRNAs on silencing viral genes at the post‐transcriptional level in COVID‐19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "As of July 7, 2020, more than 11.5 million cases of coronavirus disease 2019 (COVID-19) had been confirmed, with 0.53 million deaths globally (WHO Situation Report)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "An early viral genome sequence was published to inform and assist public health control, followed by the genome sequencing data of 60,000 samples deposited in the database curated by the ",
            "Global Initiative on Sharing All Influenza Data (GISAID)",
            " (",
            "Elbe and Buckland-Merrett, 2017",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 353,
                "end": 409,
                "name": "Global Initiative on Sharing All Influenza Data (GISAID)"
            },
            false,
            {
                "id": "T2",
                "type": "Creator",
                "start": 411,
                "end": 442,
                "name": "Elbe and Buckland-Merrett, 2017"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The diagnosis of COVID-19 is of high priority for patient and public health management to minimize spread of the infection."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Chest computed tomography (CT) imaging can be used to diagnose patients with COVID-19 (Zu et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Even though the initial RT-PCR test was negative, repeated RT-PCR tests have increased the cumulative positive rate for COVID-19 (Al-Tawfiq and Memish, 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "WHO documented the interim guidance of laboratory testing, which denotes nucleic acid amplification test (i.e. RT-PCR) should be conducted to COVID-19 suspected cases (World Health Organization, 2020a)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To date, protocols of RT-PCR assay to detect SARS-CoV-2 are designed in several countries including USA (Centers for Disease Control and Prevention [CDC]), China (China CDC), Japan (National Institute of Infectious Diseases [NIID]), Germany (Charité), France (Institut Pasteur), Hong Kong (The University of Hong Kong) and Thailand (National Institute of Health) (World Health Organization, 2020b)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The NIID assay also shows positive percent agreement (100 %, 10/10) and negative percent agreement (100 %, 15/15) compared to the result of LightMix Modular SARS and Wuhan CoV E-gene assay (Okamaoto et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We purchased the 2019-nCoV CDC qPCR Probe Assays (renamed the 2019-nCoV RUO Kit) from Integrated DNA Technologies (IDT, Coralville, IA, USA), which contains research-use-only primer and probe sets based on the protocol announced by the CDC (hereafter called the CDC assay)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The NIID has also designed an RT-PCR assay and published associated data (Shirato et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We obtained these primer and probe sets from the NIID (hereafter called the NIID assay)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The NIID assay includes two sets of primers, as well as probes containing a 5′-FAM dye and a 3’-TAMRA dye (Table 1)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We further designed double-quencher probes (purchased from IDT) based on the same primers/probe sequence reported in the NIID protocol (hereafter called the YCH assay)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These probes each incorporate a 5′-FAM dye, an internal ZEN quencher, and a 3′-Iowa Black Fluorescent Quencher (IBFQ) (Table 1)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The internal ZEN quencher was incorporated between bases 9 and 10 from the 5′ end of the probe."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "All of the primer/probe sets in the CDC, NIID, and YCH assays target the N gene of SARS-CoV-2."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The CDC assay targets three sites along the N gene, and both of the NIID and YCH assays target two sites along this gene."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "All three of the CDC, NIID, and YCH assays amplified the N gene of SARS-CoV-2 (Fig. 1",
            ")."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The CDC assay targets three sites along this gene (N1, N2, and N3), and the NIID and YCH assays target two sites (N1 and N2) (Fig. 1)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A previous study showed that the reverse primer for N1 detection in the NIID assay has one mismatch with the sequence in the current database because it was constructed based on another reported sequence (GenBank: MN908947.1) (Shirato et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "With 10 copies, we could detect amplification signals for CDC-N2, YCH-N1, YCH-N2, and NIID-N2."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We observed that the Ct values obtained for both the N1 and N2 sites with the NIID assay were relatively high compared with those obtained with the YCH assay (Fig. 2), despite the primer and probe sequences being equivalent."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The baseline fluorescence signal obtained for the N1 site with the NIID assay ranged from 150 × 104 to 200 × 104 relative fluorescence units (RFU), whereas that obtained with the YCH assay was ≤50 × 104 RFU."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Similarly, the signal obtained for the N2 site with the NIID assay ranged from 125 × 104 to 200 × 104 RFU, while that obtained with the YCH assay was 75 × 104 to 100 × 104 RFU."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To compare the assay performances of single- and double-quencher probes, we tested nasopharyngeal swabs from 66 patients using NIID and YCH assays."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Of the 66 samples, positive signals were detected in 10, 11, 17 and 18 samples by NIID-N1, YCH-N1, NIID-N2 and YCH-N2, respectively (Table 2",
            ")."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Several companies have developed commercially available kits for the RT-PCR detection of SARS-CoV-2. IDT launched an assay kit targeting three sites along the N gene and the human RPP30 gene according to the CDC protocol in USA, and this kit was used in this study."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "They showed that the CDC-N2 (USA), CDC-N3 (USA), and NIID-N2 (Japan) sets were the most sensitive and reliable laboratory tests for SARS-CoV-2."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We also observed that the CDC-N2 (USA) and NIID-N2 (Japan) assays could detect a low copy number of the DNA positive control."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Previous studies showed that the N1 site of the NIID assay is less sensitive when using the RNA positive control (Shirato et al., 2020; Ishige et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In this study, we also confirmed that the N1 site of the NIID assay has a limit of detection of 10 copies of the DNA positive control."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition, we observed that the Ct value was high for the N1 site with the NIID assay."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The amplification region of CDC-N3 partially overlapped with that of NIID-N1 and YCH-N1."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "When the amplification signal was detected in only NIID-N1 but not in NIID-N2, we think it is better to repeat test and confirm the reproducibility."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We used the primers and single-quencher probes recommended by the CDC (N1, N2 and N3) in the USA and the NIID (N1 and N2) in Japan."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition, we designed double-quencher probes according to the virus sequence provided by the NIID to develop a further assay (termed the YCH assay [N1 and N2])."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The threshold cycle (Ct) value of the RT-PCR was relatively low for the CDC and YCH assays compared with the NIID assay."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The background fluorescence signal at the baseline was lower for the YCH assay compared with the NIID assay."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We assessed the diagnostic performance between single- (NIID) and double-quencher (YCH) probes using 66 nasopharyngeal swabs."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "When the results of YCH-N2 assay were used as a reference, each assay detected SARS-CoV-2 with positive percent agreements of 56 % for NIID-N1, 61 % for YCH-N1, and 94 % for NIID-N2, and 100 % negative percent agreements for NIID-N1, YCH-N1 and NIID-N2."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), was declared a pandemic by the World Health Organisation (WHO) on 12 March 2020 after rapid global spread."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "COVID‐19 has a varied clinical presentation ranging from asymptomatic/mild infection to life‐threatening illness requiring multi‐organ support."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Data from other cohorts worldwide suggest mortality from COVID‐19 is higher in haematology patients compared to the general population,",
            ", ",
            ", ",
            " with reported mortality rates between 39% and 50% in other British haematology patient cohorts."
        ],
        "lab": [
            false,
            false,
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            ", ",
            ",",
            "In particular, a recent UK case series reported significantly higher case fatality rates in haematology patients receiving immunosuppressive or cytotoxic therapy within three months of COVID‐19 diagnosis, raising concerns about the delivery of systemic anti‐cancer therapy (SACT) during the pandemic."
        ],
        "lab": [
            false,
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We studied 55 patients ≥ 18 years old with a haematological disorder who tested positive for SARS‐CoV‐2 or were diagnosed with COVID‐19 based on radiological or clinical criteria, between 20 March and 20 April 2020."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Cases were identified through departmental surveillance which identified haematology patients testing positive for SARS‐CoV‐2 or with suspected or confirmed COVID‐19 in outpatient and inpatient departments."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This cohort included 52 patients with an underlying haematological malignancy, two with bone marrow failure syndromes and one with immune‐mediated thrombotic thrombocytopenic purpura (TTP) receiving elective immunosuppressive therapy Table I. Patients had laboratory‐confirmed SARS‐CoV‐2 [defined as a positive result on reverse‐transcriptase‐polymerase‐chain‐reaction (RT‐PCR) assay on a combined nose and throat swab specimen] or a high clinical suspicion of COVID‐19 (defined as SARS‐CoV‐2 RT‐PCR‐negative patients who had radiological evidence of pneumonia or an influenza‐like illness in the absence of another identifiable cause)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Among patients requiring hospital admission 86% (44/51) were on SACT at the time of COVID‐19 diagnosis, 87% (48/55) had a laboratory‐confirmed diagnosis of COVID‐19, 9% (5/55) were diagnosed based on radiological appearances on a plain chest radiograph (CXR) or computed tomography (CT), while 4% (2/55) had indeterminate radiology but a highly suggestive clinical picture of COVID‐19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Median age at time of COVID‐19 diagnosis was 63 (range 23–88) years, and 67% (37/55) were male."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Four patients were admitted with symptoms including cough and fever but were found to be pancytopenic and a new diagnosis of acute leukaemia/myelodysplastic syndrome (MDS) was made [two acute myeloid leukaemia (AML), one B‐cell acute lymphoblastic leukaemia (B‐ALL), one high‐risk MDS] with concomitant COVID‐19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Two patients were admitted to hospital for management of their haematological malignancy and were asymptomatic or had mild symptoms of COVID‐19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Four patients had been in hospital for greater than seven days before they developed symptoms and thus likely acquired COVID‐19 in hospital."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Four patients were neutropenic (neuts < 1 × 109/l) at time of COVID‐19 diagnosis."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Thirteen percent (7/55) developed neutropenia (<1 × 109/l) in the seven days following COVID‐19 diagnosis."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Of those who were currently on or had recently received SACT, 65% (34/52) had their therapy modified by dose change (n = 1), treatment delay (n = 28) and/or a change in treatment regimen (n = 5) due to concerns regarding the administration of standard chemotherapy during the COVID‐19 pandemic and in line with national guidance."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These regimens were felt to be less myelosuppressive compared to standard therapy."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            ", ",
            " A patient with a new diagnosis of Philadelphia‐positive B‐ALL and a mild clinical presentation of COVID‐19 underwent reduced‐intensity imatinib‐based induction therapy on the UKALL60+ protocol."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "All four patients recovered from COVID‐19 despite undergoing induction therapy during their illness."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In all, 86% (43/50) of patients received systemic antibiotics, and 6% (3/50) antifungal therapy during their COVID‐19 illness."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A number of patients had other concomitant infections diagnosed during their COVID‐19 admission (Table SIII)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We report the outcomes of a large cohort of haematology patients with COVID‐19, the majority of whom were receiving SACT."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Despite valid concerns regarding the vulnerability of haematology patients to COVID‐19, our observed mortality of 37% in hospitalised patients indicates that a significant proportion of haematology patients recover from COVID‐19, despite recent or concurrent SACT."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Despite heterogeneity in our patient cohort and methodology, the mortality rate described here is consistent with those from other UK cohorts of patients with haematological malignancy and COVID‐19 (39–52%)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            ", ",
            ",",
            "While a direct comparison with a non‐haematology cohort has not been performed, our data corroborate existing studies that haematology patients are at increased risk of severe disease and mortality from COVID‐19, with a large UK population study reporting lower mortality of 33% of all hospitalised cases, despite an older median study age of 72 years."
        ],
        "lab": [
            false,
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Several risk factors for severe COVID‐19 in the general population are relevant to patients with haematological disorders."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In this patient cohort, 81% had SACT modifications (delay or de‐intensification) in light of their COVID‐19 diagnosis, including when receiving induction treatment for new diagnoses of haematological malignancies, in line with emerging evidence and guidance."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "While patients who received SACT within 28 days of COVID‐19 diagnosis had higher rates of severe disease and mortality, this was not statistically significant, although analysis is limited by the size and heterogeneity of the cohort."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "While a recent UK series has suggested that recent SACT confers a higher risk of death from COVID‐19 in haemato‐oncology patients,",
            " two recent multicentre cohort studies including haematology patients have found no impact of SACT timing on COVID‐19 outcome,",
            ", ",
            " highlighting the need for further data regarding the implications for different disease subtypes and treatment modalities."
        ],
        "lab": [
            false,
            false,
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "While caution in instituting SACT is clearly warranted, our data suggest that modification of therapy including the use of non‐standard treatment regimens can be considered in haematology patients with COVID‐19 to allow treatment of the haematological diagnosis while accepting risks of COVID‐19 infection."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Where the COVID‐19 pandemic has forced a paradigm shift in therapy, the long‐term follow‐up of these patients will be crucial to assess efficacy in comparison to more intensive chemotherapy‐based regimens."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Furthermore, the cases of newly diagnosed leukaemia highlight the importance of COVID‐19 testing as part of routine investigation of patients with haematological malignancies in the current climate."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Recent data from patients in the general population with COVID‐19 have identified that haematological parameters including anaemia or thrombocytopenia are risk factors for severe disease."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            ",",
            "Coagulopathy in COVID‐19 pathophysiology is an ongoing area of research, with early observations highlighting high rates of VTE occurrence, particularly in those with severe COVID‐19."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            ", ",
            ", ",
            ", ",
            " Prophylactic LMWH, unless contraindicated, is, therefore, advised for all COVID‐19 patients."
        ],
        "lab": [
            false,
            false,
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Summary  Haematology patients receiving chemo‐ or immunotherapy are considered to be at greater risk of COVID‐19‐related morbidity and mortality."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We aimed to identify risk factors for COVID‐19 severity and assess outcomes in patients where COVID‐19 complicated the treatment of their haematological disorder."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A retrospective cohort study was conducted in 55 patients with haematological disorders and COVID‐19, including 52 with malignancy, two with bone marrow failure and one immune‐mediated thrombotic thrombocytopenic purpura (TTP)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "COVID‐19 diagnosis coincided with a new diagnosis of a haematological malignancy in four patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Among patients, 82% were on systemic anti‐cancer therapy (SACT) at the time of COVID‐19 diagnosis."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The majority of patients recovered from COVID‐19, despite receiving recent SACT."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This suggests that SACT, where urgent, should be administered despite intercurrent COVID‐19 infection, which should be managed according to standard pathways."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A promising approach to combat the COVID19 pandemic involves development of antiviral antibodies targeting the spike protein of SARS-CoV-2."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Antibodies targeting the spike protein of SARS-CoV-2 present a promising approach to combat the COVID19 pandemic; however, concerns remain that mutations can yield antibody resistance."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To seek potential Chinese herbal medicine (CHM) for the treatment of coronavirus disease 2019 (COVID-19) through the molecular docking of the medicine with SARS-CoV-2 3CL hydrolytic enzyme and the angiotensin converting enzyme II(ACE2) as receptors, using computer virtual screening technique, so as to provide a basis for combination forecasting."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Based on the perspective of network pharmacology, the chemical-target network was constructed, and the functional enrichment analysis of gene ontology and the pathway enrichment analysis of Kyoto encyclopedia of genes and genomes were carried out by DAVID to speculate about the mechanism of action of the core drug pairs."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Among 238 potential anti-COVID-19 herbs screened in total, 16 kinds of CHM containing the most active ingredients, and 5 candidate anti-COVID-19 herbs that had been used in high frequency, as well as a core drug pair, namely, Forsythiae Fructus-Lonicerae Japonicae",
            "The core drug pair of Forsythiae Fructus-Lonicerae Japonicae Flos containing multiple components and targets is easy to combine with 3CLpro and ACE2, and exerts an anti-COVID-19 pneumonia effect through multi-component and multi-target, and plays the role of anti-COVID-19 pneumonia in multi-pathway."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "National guidelines are being issued to provide continuous adult cancer care without increasing the risk of COVID infection [9], [10]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Gy; SIB schedules are incorporated into the FaR-RMS radiotherapy guidelines."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The coronavirus disease 2019 (COVID-19), is caused by severe acute respiratory syndrome corona virus-2 (SARS-CoV-2), has emerged from Wuhan, China, in December 2019 [1] and spread rapidly across worldwide."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "On 11th March 2020, the World Health Organization (WHO) declared COVID-19 as a pandemic (https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "ACE2 receptor plays a crucial role in cellular invading of SARS-CoV-2 as well as various pathophysiological conditions of the COVID-19 [16]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "However, in the present report, we observed a positive correlation of allele D with infection an mortality rate of COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The minor allele of ACE I/D was linked with COVID-19 mortality in the Asian population."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Several reports have been highlighted the importance of ACE-2 on the pathogenesis of COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Data on COVID-19 infection rate (per million), mortality/million, and percentage of recovery were acquired form ",
            "worldometer",
            " website."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 986,
                "end": 997,
                "name": "worldometer"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The COVID-19 pandemic poses unprecedented challenges to the field of oncology."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "I read with great interest the recent recommendations outlined by Deitz et al. for patients with breast cancer during the COVID-19 pandemic [1]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "COVID‐19 is a severe acute respiratory syndrome caused by SARS‐CoV‐2 that affected in the last few months more than 12 million individuals around the world (https://covid19.who.int/)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A recent study by Ellinghaus et al, investigating a large cohort of COVID‐19 patients from Italy and Spain, using a genome‐wide association study approach, did not find any significant evidence of HLA involvement."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Reads were analyzed using the HLA TypeStream Visual Software (One Lambda), ver. 1.3, updated to the ",
            "IPD‐IMGT/HLA",
            " last database release, 3.40.0."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 498,
                "end": 510,
                "name": "IPD‐IMGT/HLA"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In Table 2, we also show the HLA alleles distribution of the 99 COVID‐19 patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The increased frequencies that we observed for DRB1*15:01 and DQB1*06:02, in strong linkage disequilibrium with each other, in the 99 severe affected COVID‐19 Italian patients were not in line with the results obtained on a larger survey studied by Ellinghaus et al",
            " that did not show any association between HLA and COVID‐19, but confirmed those published by Kachuri et al",
            " identifying these two alleles among seven HLA susceptibility alleles."
        ],
        "lab": [
            false,
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "With the aim to individuate alleles that may reflect a higher susceptibility to the disease, in the present study we analyzed the HLA allele frequency distribution in a group of 99 Italian patients affected by a severe or extremely severe form of COVID‐19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The increased frequencies observed may contribute to identify potential markers of susceptibility to the disease, although controversial results on the role of single HLA alleles in COVID‐19 patients have been recently reported."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Variables from the EHR were chosen for this analysis based on a combination of their prevalence per patient across the dataset, relevance to COVID-19 based on previous literature and empirical evidence, and the goals of this study."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Based on the utility of these lab values in clinical practice and the similarity between their statistical distributions, labs derived from a VBG or BMP were collapsed into a single category (i.e., “SODIUM”), and arterial labs were not incorporated as features in these analyses."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Of 2864 patients discharged alive following hospitalization for COVID-19, 103 (3.6%) returned to one of five hospitals within 14 days, with 56 (54.4%) readmitted and the remaining 47 (45.6%) discharged or left from the emergency department (ED) (Table 1)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Though lower BMI could serve as a marker for and has been associated with worse health outcomes in other disease states, the distributions of BMI between those returning to the hospital and those who did not were relatively similar (Supplementary Figure 1) with a low difference in means; therefore, further work is needed to unravel the association between BMI and outcomes in COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Background  Data on patients with coronavirus disease 2019 (COVID-19) who return to hospital after discharge are scarce."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To describe clinical characteristics of patients with COVID-19 who returned to the emergency department (ED) or required readmission within 14 days of discharge."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Conclusions  Return to hospital after admission for COVID-19 was infrequent within 14 days of discharge."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "With COVID-19, the time and place a biosample was collected has suddenly become a life and death issue."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "SARS CoV‐2, the virus which causes COVID19, is similar to, but not identical with the SARS‐CoV‐1 virus, which caused the SARS epidemic originating in China in 2002 to 2003."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "For example, analyses of different strains showed that predominance of COVID‐19 cases in the New York City area resulted largely from infected patients who flew in from Europe, rather than Asia."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Consequently, barring US entry to recent visitors to China on January 31st, and from European countries on March 11th was largely ineffective in preventing the COVID outbreak in the United States."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The impact of the COVID‐19 epidemic suggests that interest in the development of a vaccine will be more enduring."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The COVID‐19 epidemic was not the first coronavirus epidemic of this century and represents one of the increasing number of zoonoses from wildlife to impact global health."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "SARS CoV‐2, the virus causing the COVID‐19 epidemic is distinct from, but closely resembles SARS CoV‐1, which was responsible for the severe acute respiratory syndrome (SARS) outbreak in 2002."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We review recent coronavirus‐related epidemics and distinguish clinical and molecular features of CoV‐2, the causative agent for COVID‐19, and review the current status of vaccine trials."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "One set of questions involves susceptibility and outcomes related to SARS-CoV-2 infection (COVID-19)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Large, international studies and collaborations have formed to investigate host genetic factors related to COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These investigations include analyses of existing public and private datasets, as well as the establishment of new cohorts (e.g., see “",
            "The COVID-19 Host Genetics Initiative",
            "” and “23andMe/23andMe Research Blog” entries in the Web Resources)."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 354,
                "end": 391,
                "name": "The COVID-19 Host Genetics Initiative"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We use themes identified in our review of these articles to highlight areas that are particularly relevant to human studies of COVID-19; in addition to the limited references cited here, please refer to Table S1 for the additional literature identified through this search, as well as section-specific references not included in the main manuscript."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In the burgeoning studies of COVID-19 host genetic factors, controlling for these types of other variables will be challenging and important."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Similar approaches have achieved significant results for other etiologically and medically complex diseases (such as preterm birth), including using some of the same datasets and approaches being proposed for COVID-19 studies."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This aspect bears further scrutiny in COVID-19 studies, especially given recent data regarding SARS-CoV-2 genetic changes detected in different areas of the world (e.g., see data from ",
            "Nextstrain",
            " under Web Resources)."
        ],
        "lab": [
            false,
            {
                "id": "T2",
                "type": "Repository",
                "start": 1363,
                "end": 1373,
                "name": "Nextstrain"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Related to the human implications of this type of work, newer gene editing techniques may be an efficient way to provide experimental validation of specific variants that have been implicated in COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This line of reasoning may also be relevant to age-specific differences observed with COVID-19 in humans."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "That is, one of several potential factors that may explain why most children are more mildly affected by COVID-19 is age-related differences in ACE2 receptor expression."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Several studies have used (and are using) existing datasets to explore allele frequencies (such as in ACE2) in various geographic/ancestral populations: the hypothesis is that differences in allele frequencies—as well as observed differences in gene expression—may be one reason for differential impacts of COVID-19 in different parts of the world.,",
            "Only studies reporting ORs and CIs are shown (PMID: ",
            "32348495",
            " did not include CI)."
        ],
        "lab": [
            false,
            false,
            {
                "id": "T3",
                "type": "AccessionNumber",
                "start": 2279,
                "end": 2287,
                "name": "32348495"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Validating findings with biological data will also be helpful—for example, a recent study on COVID-19 showed that certain immune mediators, cytokines, and chemokines correlate with aspects of disease."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Because of today’s availability of genomic approaches, and in contrast to the previously published studies (described in Tables 1 and S2), emerging studies on COVID-19 will most likely have to consider both rare and common variants in these and other genes, as well as combinatorial models explaining susceptibility and outcomes."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "SARS-CoV-2 studies have suggested that truncated ACE2 could act as a COVID-19 therapeutic through inhibition of SARS-CoV-2 spike protein activity."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Modern gene editing techniques have been studied in this context; these have also garnered recent interest in COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In COVID-19, the use of splice-switching antisense oligonucleotides has been proposed to affect ACE2 in order to limit SARS-CoV-2 entry."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "As with other questions in COVID-19 (e.g., ethical questions pertaining to human challenge studies in vaccine trials), balancing risks and benefits will be critical."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Studies of cheetahs present an interesting example related to MHC genes, which may have connections to human COVID-19 studies."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In humans, severe COVID-19 outcomes have already been reported in peer-reviewed literature (as well as many lay articles), but specific suggestions of associations with consanguinity have not been identified."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The HLA genes remain a logical target of interest in relation to COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "An in silico analysis of viral peptide-MHC class I binding affinity in relation to HLA genotypes for SARS-CoV-2 peptides, as well as potential cross-protective immunity related to four common human coronaviruses, provides evidence that HLA-B∗46:01 may be associated with COVID-19 vulnerability, whereas HLA-B∗15:03 may enable cross-protective T-cell-based immunity."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Work in humans so far has also concentrated on key immune genes (see Tables 1 and S2); similar work in relation to COVID-19 has been proposed."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "An example of a population-specific consideration has already been mentioned in relation to COVID-19 is that a variant in SCN5A (MIM: ",
            "600163",
            ") that is common in individuals of recent African descent may increase the risk of cardiovascular morbidity and mortality, including upon exposure to hydroxychloroquine and azithromycin."
        ],
        "lab": [
            false,
            {
                "id": "T4",
                "type": "AccessionNumber",
                "start": 4464,
                "end": 4470,
                "name": "600163"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Specific examples have already been reported in the literature on COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Another area of interest may involve studying individuals with identified pathogenic or severe variants (e.g., “human knockouts”) to determine correlations with COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Currently, age appears to be strongly correlated with COVID-19 outcomes."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Human host genetic studies on coronavirus have been largely candidate driven to date (see Tables 1 and S2 and Figures 3 and 4 for details on human studies, including specific references), though many hypothesis-free studies on COVID-19 are in various phases of completion."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Previously, lists of recommended secondary genes have been compiled in general contexts, and recommendations have been made about informing individuals about these findings (prior to the COVID-19 pandemic)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "With COVID-19, genomic investigators have newly assembled lists of secondary genetic information that may be relevant to the pandemic."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Beyond this overarching framework, specific papers have already been published about pharmacogenomic considerations for medications, such as anti-IL-6 agents for the treatment of COVID-19 (as well as hydroxychloroquine and azithromycin).,",
            "Details of the human studies are presented in the section on Literature Search and Sources, and in Table 1, S2, and Figures 3, 4, and 5."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition to the germline variants described in these previous studies, non-germline changes are discussed as possibly pertinent to COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Correlations between clonal hematopoiesis and COVID-19 mortality have been suggested, as have the potential importance of tumor-based ACE2 genetics and epigenetics."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "MERS and SARS-CoV-1 are severe, but the fact that these epidemics were limited more than the COVID-19 pandemic may have fortunately led to a lack of cases to conduct traditional association studies (unlike some other respiratory infections leading to more widespread disease)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The literature already reflects specific guidance and lessons learned for many genetic conditions, such as Charcot-Marie-Tooth, G6PD deficiency, Gaucher disease, inherited arrhthymias, and inborn errors of metabolism (see Table S3 for references for COVID-19 guidance related to these conditions)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition to these pragmatic guidelines, understanding gained from studying the impact of COVID-19 on people with these rare diseases may yield insights that can be applied to the population at large, much like how unraveling the causes of primary immunodeficiencies can lead to generalizable knowledge about the immune system."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We outline key genes and loci from animal and human host genetic studies that may bear investigation in the study of COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We outline key genes and loci from animal and human host genetic studies that may bear investigation in the study of COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Travel-associated cases of coronavirus disease 2019 (COVID-19) were reported outside of China as early as January 13, 2020, and the virus has subsequently spread to nearly all nations (World Health Organization, 2020a, World Health Organization, 2020b)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The majority of early COVID-19 cases in the United States were (1) associated with travel to a “high-risk” country or (2) close contacts of previously identified cases according to the testing criteria adopted by the Centers for Disease Control and Prevention (CDC) (Centers for Disease Control and Prevention, 2020b)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "From March 1–19, 2020, the number of reported COVID-19 cases in the United States rapidly increased from 74 to 13,677, and the virus was detected in all 50 states (Dong et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "It was recently estimated that the true number of COVID-19 cases in the United States is likely in the tens of thousands (Perkins et al., 2020), suggesting substantial undetected infections and spread within the country."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We hypothesized that, with the growing number of COVID-19 cases in the United States and the large volume of domestic travel, new United States outbreaks are now more likely to result from interstate rather than international spread."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To delineate the roles of domestic and international virus spread in the emergence of new United States COVID-19 outbreaks, we sequenced SARS-CoV-2 viruses collected from cases identified in Connecticut."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We sequenced SARS-CoV-2 genomes from nine of the first COVID-19 cases reported in Connecticut, with sample collection dating from March 6–14, 2020 (Data S1)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We shared the genomes of these viruses publicly as we generated them (",
            "GISAID",
            " ",
            "EPI_ISL_416416-416424",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 1644,
                "end": 1650,
                "name": "GISAID"
            },
            false,
            {
                "id": "T2",
                "type": "AccessionNumber",
                "start": 1651,
                "end": 1672,
                "name": "EPI_ISL_416416-416424"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T1",
                "end": "T2"
            }
        ]
    },
    {
        "sen": [
            "We combined our genomes with other publicly available sequences for a final dataset of 168 SARS-CoV-2 genomes (Figure 1; Data S2)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The dataset can be visualized on our “community” ",
            "Nextstrain",
            " page (",
            "https://nextstrain.org/community/grubaughlab/CT-SARS-CoV-2/paper1",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T3",
                "type": "Repository",
                "start": 1855,
                "end": 1865,
                "name": "Nextstrain"
            },
            false,
            {
                "id": "T4",
                "type": "URL",
                "start": 1872,
                "end": 1937,
                "name": "https://nextstrain.org/community/grubaughlab/CT-SARS-CoV-2/paper1"
            },
            false
        ],
        "rel": [
            {
                "id": "R2",
                "bool": true,
                "head": "T3",
                "end": "T4"
            }
        ]
    },
    {
        "sen": [
            "Regardless, neither the CT-Yale-001 nor the CT-Yale-006 COVID-19 cases were travel-associated, which indicates that these patients were part of domestic transmission chains that stemmed from undetected introductions."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Importantly, our data indicate that, by early to mid-March, there had already been interstate spread during the early COVID-19 epidemic in the United States."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Our phylogenetic analysis shows that the COVID-19 outbreak in Connecticut was driven, in part, by domestic virus introductions."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "(E) We calculated importation risk by modeling the number of daily prevalent COVID-19 cases in each potential importation source and then estimating the number of infected travelers using the daily air travel volume from each location."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We first estimated daily passenger volumes arriving in the region from the five countries (China, Italy, Iran, Spain, and Germany) and out-of-region states (Washington, California, Florida, Illinois, and Louisiana) that have reported the most COVID-19 cases to date (Figures 2A–2D)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We found that the daily domestic passenger volumes were ∼100 times greater than international in Hartford, ∼10 times greater in Boston, and ∼4 times greater in New York in our dataset (Figure 2B)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "By combining daily passenger volumes (Figure 2B) with COVID-19 prevalence at the travel route origin (Figures 2C and 2D) and accounting for differences in reporting rates, we found that the domestic and international SARS-CoV-2 importation risk started to increase dramatically at the beginning of March 2020 (Figure 2E)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Because of the overall low prevalence of COVID-19 in China, we did not find any significant effects of travel restrictions from China that were enacted on February 1 (Data S3)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The dramatic rises in domestic and international importation risk preceded the state-wide COVID-19 outbreak in Connecticut (Figure 2E), and the recent increase in risk of domestic importation may give rise to new outbreaks in the region."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We therefore propose that a unified effort to detect and prevent new COVID-19 cases will be essential for mitigating the risk of future domestic outbreaks."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "If spread between states is now occurring, as our results indicate, then the United States will struggle to control COVID-19 in the absence of a unified surveillance strategy."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To investigate the origin and diversity of SARS-CoV-2 in Connecticut, we compiled a dataset of our nine genomes with another 159 representative sample of SARS-CoV-2 genomes that were available from ",
            "GenBank",
            " (",
            "https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/",
            ") and ",
            "GISAID",
            " (",
            "https://www.gisaid.org/",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T5",
                "type": "Repository",
                "start": 4426,
                "end": 4433,
                "name": "GenBank"
            },
            false,
            {
                "id": "T6",
                "type": "URL",
                "start": 4435,
                "end": 4488,
                "name": "https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/"
            },
            false,
            {
                "id": "T7",
                "type": "Dataset",
                "start": 4494,
                "end": 4500,
                "name": "GISAID"
            },
            false,
            {
                "id": "T8",
                "type": "URL",
                "start": 4502,
                "end": 4525,
                "name": "https://www.gisaid.org/"
            },
            false
        ],
        "rel": [
            {
                "id": "R3",
                "bool": true,
                "head": "T5",
                "end": "T6"
            },
            {
                "id": "R4",
                "bool": true,
                "head": "T7",
                "end": "T8"
            }
        ]
    },
    {
        "sen": [
            "No data that was only released on ",
            "GISAID",
            " was used without consent from the authors (see Acknowledgments)."
        ],
        "lab": [
            false,
            {
                "id": "T9",
                "type": "Dataset",
                "start": 4562,
                "end": 4568,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Root-to-Tip Plot Showing the Evolutionary Rate of the SARS-CoV-2 Genomes in Our Dataset, Related to Figure 1",
            "Daily COVID-19 cases from international locations were obtained from the ",
            "European Centre for Disease Prevention and Control",
            " via ",
            "Our World in Data",
            " (",
            "https://ourworldindata.org/coronavirus-source-data",
            ")."
        ],
        "lab": [
            false,
            false,
            {
                "id": "T10",
                "type": "Creator",
                "start": 4816,
                "end": 4866,
                "name": "European Centre for Disease Prevention and Control"
            },
            false,
            {
                "id": "T11",
                "type": "Repository",
                "start": 4871,
                "end": 4888,
                "name": "Our World in Data"
            },
            false,
            {
                "id": "T12",
                "type": "URL",
                "start": 4890,
                "end": 4940,
                "name": "https://ourworldindata.org/coronavirus-source-data"
            },
            false
        ],
        "rel": [
            {
                "id": "R5",
                "bool": true,
                "head": "T10",
                "end": "T12"
            },
            {
                "id": "R6",
                "bool": true,
                "head": "T11",
                "end": "T12"
            }
        ]
    },
    {
        "sen": [
            "Daily COVID-19 cases from Connecticut and other U.S. locations (Washington, California, Florida, Illinois, and Louisiana) were obtained from the repository (",
            "https://github.com/CSSEGISandData/COVID-19",
            ") hosted by the ",
            "Center for Systems Science and Engineering (CSSE) at Johns Hopkins University",
            " (Dong et al., 2020)."
        ],
        "lab": [
            false,
            {
                "id": "T13",
                "type": "URL",
                "start": 5100,
                "end": 5142,
                "name": "https://github.com/CSSEGISandData/COVID-19"
            },
            false,
            {
                "id": "T14",
                "type": "Creator",
                "start": 5158,
                "end": 5235,
                "name": "Center for Systems Science and Engineering (CSSE) at Johns Hopkins University"
            },
            false
        ],
        "rel": [
            {
                "id": "R7",
                "bool": true,
                "head": "T14",
                "end": "T13"
            }
        ]
    },
    {
        "sen": [
            "These represent the international and out-of-region domestic (i.e., excluding New York, Massachusetts, and New Jersey) locations with the most reported COVID-19 cases."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The novel coronavirus SARS-CoV-2 was first detected in the Pacific Northwest region of the United States in January 2020, with subsequent COVID-19 outbreaks detected in all 50 states by early March."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To uncover the sources of SARS-CoV-2 introductions and patterns of spread within the United States, we sequenced nine viral genomes from early reported COVID-19 patients in Connecticut."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Graphical Abstract      Highlights     •  Connecticut’s COVID-19 outbreak resulted from multiple domestic virus introductions    •  SARS-CoV-2 genomic data indicate that coast-to-coast spread occurred in the United States    •  Risk of introduction by domestic air travel exceeded international travel in March    •  Restrictions on international travel did not significantly alter risk estimates      Using genomics and air travel information, the spread of SARS-CoV-2 in the United States from coast to coast is shown to be more a consequence of domestic introductions than of international travel."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The third, SARS-CoV-2, causes the severe respiratory disease coronavirus disease 2019 (COVID-19) (Gorbalenya et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The June 21, 2020 World Health Organization (WHO) Situation Report records over 8.7 million COVID-19 cases and 460,000 deaths, numbers that increase daily."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Phylogenetic analysis of the global sampling of SARS-CoV-2 is being very capably addressed by the ",
            "Global Initiative for Sharing All Influenza Data (GISAID)",
            " database (",
            "https://www.gisaid.org",
            "/;",
            "Our analysis pipeline to track SARS-CoV-2 mutations in the COVID-19 pandemic is based on regular updates from the ",
            "GISAID",
            " SARS-CoV-2 sequence database (",
            "GISAID",
            " acknowledgments are in Table S1)."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 378,
                "end": 435,
                "name": "Global Initiative for Sharing All Influenza Data (GISAID)"
            },
            false,
            {
                "id": "T2",
                "type": "URL",
                "start": 446,
                "end": 468,
                "name": "https://www.gisaid.org"
            },
            false,
            false,
            {
                "id": "T3",
                "type": "Dataset",
                "start": 585,
                "end": 591,
                "name": "GISAID"
            },
            false,
            {
                "id": "T4",
                "type": "Dataset",
                "start": 622,
                "end": 628,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T1",
                "end": "T2"
            }
        ]
    },
    {
        "sen": [
            "",
            "GISAID",
            " sequences are generally linked to the location and date of sampling."
        ],
        "lab": [
            false,
            {
                "id": "T5",
                "type": "Dataset",
                "start": 663,
                "end": 669,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Hundreds of new SARS-CoV-2 sequences are added to ",
            "GISAID",
            " each day, so we have automated steps to create daily working alignments (Kurtz et al., 2004; Figure S1)."
        ],
        "lab": [
            false,
            {
                "id": "T6",
                "type": "Dataset",
                "start": 789,
                "end": 795,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The analysis presented here is based on a May 29, 2020 download of the ",
            "GISAID",
            " data, when our Spike alignment included 28,576 sequences; updated versions of key figures can recreated at our website (https://cov.lanl.gov)."
        ],
        "lab": [
            false,
            {
                "id": "T7",
                "type": "Dataset",
                "start": 972,
                "end": 978,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This allows daily processing of ",
            "GISAID",
            " data to enable us to track mutations."
        ],
        "lab": [
            false,
            {
                "id": "T8",
                "type": "Dataset",
                "start": 1154,
                "end": 1160,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These steps are incorporated in a single Perl script, ‘align_to_ref.pl’, briefly summarized here: sequences are compressed for identity, then mapped against the given reference sequence using ‘nucmer’ from the ‘MUMmer’ package (Kurtz et al., 2004)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "At that time, the G614 form was rare globally but gaining prominence in Europe, and ",
            "GISAID",
            " was also tracking the clade carrying the D614G substitution, designating it the “G clade.”",
            "The figures shown here can be recreated with contemporary data from ",
            "GISAID",
            " at the http://cov.lanl.gov/",
            "(A) Analysis summaries for all of the level 3 and 4 regional subdivisions from ",
            "GISAID",
            " data (Figure 1) that have at least 5 each of D614 and G614 variants and that are sampled on at least 14 days."
        ],
        "lab": [
            false,
            {
                "id": "T9",
                "type": "Dataset",
                "start": 1532,
                "end": 1538,
                "name": "GISAID"
            },
            false,
            false,
            {
                "id": "T10",
                "type": "Dataset",
                "start": 1698,
                "end": 1704,
                "name": "GISAID"
            },
            false,
            false,
            {
                "id": "T11",
                "type": "Dataset",
                "start": 1812,
                "end": 1818,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In the May 29, 2020 dataset used here, Santa Clara county was sampled later in May than any other region in California, so the California G614 frequency dips at this last available time point."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "(Confirmed COVID19 case count data from: ",
            "COVID-19 Data Repository",
            " by the ",
            "Center for Systems Science and Engineering (CSSE)",
            " at Johns Hopkins University)."
        ],
        "lab": [
            false,
            {
                "id": "T12",
                "type": "Repository",
                "start": 2163,
                "end": 2187,
                "name": "COVID-19 Data Repository"
            },
            false,
            {
                "id": "T13",
                "type": "Creator",
                "start": 2195,
                "end": 2244,
                "name": "Center for Systems Science and Engineering (CSSE)"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Each geographic region that meets these criteria is extracted separately based on the hierarchical geographic/political levels designated in ",
            "GISAID",
            " (Figure 1B)."
        ],
        "lab": [
            false,
            {
                "id": "T14",
                "type": "Dataset",
                "start": 2416,
                "end": 2422,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Only limited recent sampling from Asia is currently available in ",
            "GISAID",
            "; to include more samples on the map the 10-day period between March 11-20, is shown rather than the period between March 21-30; even the limited sampling mid-March the supports the repeated pattern of a shift to G614."
        ],
        "lab": [
            false,
            {
                "id": "T15",
                "type": "Dataset",
                "start": 2501,
                "end": 2507,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In mid-March 2020, screening began to include the local population; this coincided with the appearance of the D614 variant in the sequence dataset."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A June 19, 2020 ",
            "GISAID",
            " update for several California counties is provided in Figure S4C, and the G614 form is present in the most recent Santa Clara DPH samples."
        ],
        "lab": [
            false,
            {
                "id": "T16",
                "type": "Dataset",
                "start": 2890,
                "end": 2896,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "C. Updated data regarding California from the June 19, 2020 ",
            "GISAID",
            " sampling."
        ],
        "lab": [
            false,
            {
                "id": "T17",
                "type": "Dataset",
                "start": 3096,
                "end": 3102,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Most of the analysis in this paper was undertaken using the May 29, 2020 ",
            "GISAID",
            " download, but as California was an interesting outlier, and more recent sampling conducted while the paper was under review was informative, we have included some additional plots from California data that were available at the time of our final response to review, on June 19th."
        ],
        "lab": [
            false,
            {
                "id": "T18",
                "type": "Dataset",
                "start": 3186,
                "end": 3192,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Santa Clara DPH, which was essentially all D614 in our May 29th ",
            "GISAID",
            " download, had 7 G614 forms sampled in late May that were evident in our June 19th ",
            "GISAID",
            " download."
        ],
        "lab": [
            false,
            {
                "id": "T19",
                "type": "Dataset",
                "start": 3537,
                "end": 3543,
                "name": "GISAID"
            },
            false,
            {
                "id": "T20",
                "type": "Dataset",
                "start": 3626,
                "end": 3632,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Our second statistical approach to evaluating the significance of the D614-to-G614 transition (Figure 3) uses the time series data in ",
            "GISAID",
            " more fully."
        ],
        "lab": [
            false,
            {
                "id": "T21",
                "type": "Dataset",
                "start": 3777,
                "end": 3783,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Here we extracted all regional data from ",
            "GISAID",
            " that had a minimum of 5 sequences representing each of the D614 and the G614 variants and at least 14 days of sampling."
        ],
        "lab": [
            false,
            {
                "id": "T22",
                "type": "Dataset",
                "start": 3837,
                "end": 3843,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The earliest examples of sequences carrying parts of the 4-mutation haplotype that characterizes the D614G ",
            "GISAID",
            " G clade were found in China and Germany in late January 2020, and they carried 3 of the 4 mutations that define the clade, lacking only the RdRp P323L substitution (Figure S5D)."
        ],
        "lab": [
            false,
            {
                "id": "T23",
                "type": "Dataset",
                "start": 4071,
                "end": 4077,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "B. The ",
            "GISAID",
            " G clade is based on a 4 base haplotype that distinguishes it from the original Wuhan form."
        ],
        "lab": [
            false,
            {
                "id": "T24",
                "type": "Dataset",
                "start": 4263,
                "end": 4269,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The missing RBD residues at the ACE2 interface are shown in (D)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "SARS-CoV-2 sequences from 999 individuals presenting with COVID-19 disease at the Sheffield Teaching Hospitals NHS Foundation Trust were available and linked to clinical data."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Similar results, reported recently in a preprint that has not yet been peer reviewed, also suggest that G614 increases Spike stability and membrane incorporation (Zhang et al., 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "(A) A recombinant VSV pseudotyped with the G614 Spike grows to a higher titer than D614 Spike in Vero, 293T-ACE2, and 293T-ACE2-TMPRSS2 cells, as measured in terms of focus-forming units (ffu)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The mutation resulting in the signal peptide L5F change recurs many times in the tree and is stably maintained in about 0.6% of the global ",
            "GISAID",
            " data."
        ],
        "lab": [
            false,
            {
                "id": "T25",
                "type": "Dataset",
                "start": 5119,
                "end": 5125,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The tree is rooted on a reference sequence derived from the original Wuhan isolates (",
            "GenBank",
            " accession number ",
            "NC_045512",
            "), at the 3 o’clock position."
        ],
        "lab": [
            false,
            {
                "id": "T26",
                "type": "Repository",
                "start": 5217,
                "end": 5224,
                "name": "GenBank"
            },
            false,
            {
                "id": "T27",
                "type": "AccessionNumber",
                "start": 5242,
                "end": 5251,
                "name": "NC_045512"
            },
            false
        ],
        "rel": [
            {
                "id": "R2",
                "bool": true,
                "head": "T26",
                "end": "T27"
            }
        ]
    },
    {
        "sen": [
            "As an example, in this tree, the region from approximately 12:30 to 3 o’clock represents ",
            "GISAID",
            "’s “GR” clade, defined both by mutations we are tracking in this paper that carry the G614 variant (the ",
            "GISAID",
            " G clade, defined by mutations A23403G, C14408T, C3037T, and a mutation in the 5′ UTR (C241T, not shown here), and an additional 3-position polymorphism: G28881A + G28882A + G28883C."
        ],
        "lab": [
            false,
            {
                "id": "T28",
                "type": "Dataset",
                "start": 5370,
                "end": 5376,
                "name": "GISAID"
            },
            false,
            {
                "id": "T29",
                "type": "Dataset",
                "start": 5480,
                "end": 5486,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These base substitutions are contiguous and result two amino acid changes, including N-G204R, hence ",
            "GISAID",
            "’s “GR clade” name."
        ],
        "lab": [
            false,
            {
                "id": "T30",
                "type": "Dataset",
                "start": 5769,
                "end": 5775,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Close examination of this triplet in sequences from the Sheffield dataset suggests the mutations are not a sequencing artifact."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The ",
            "GISAID",
            " data, however, provided the opportunity to look into the relationships among the SARS-CoV-2 variants in the context of time and geography, enabling us to track the increase in frequency of G614 as an early indicator of possible positive selection."
        ],
        "lab": [
            false,
            {
                "id": "T31",
                "type": "Dataset",
                "start": 5927,
                "end": 5933,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The ",
            "Global Initiative for Sharing All Influenza Data (GISAID)",
            " (",
            "Elbe and Buckland-Merrett, 2017",
            "; ",
            "Shu and McCauley, 2017)",
            " has been coordinating SARS-CoV-2 genome sequence submissions and making data available for download since early in the pandemic."
        ],
        "lab": [
            false,
            {
                "id": "T32",
                "type": "Dataset",
                "start": 6186,
                "end": 6243,
                "name": "Global Initiative for Sharing All Influenza Data (GISAID)"
            },
            false,
            {
                "id": "T33",
                "type": "Creator",
                "start": 6245,
                "end": 6276,
                "name": "Elbe and Buckland-Merrett, 2017"
            },
            false,
            {
                "id": "T34",
                "type": "Creator",
                "start": 6278,
                "end": 6301,
                "name": "Shu and McCauley, 2017)"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To assemble a high-quality dataset for mutational analysis, we constructed a data pipeline using some off-the-shelf bioinformatic tools and a small amount of custom code."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The MSA was refined using code derived from the ",
            "Los Alamos HIV",
            " database “Gene Cutter” tool code base."
        ],
        "lab": [
            false,
            {
                "id": "T35",
                "type": "Repository",
                "start": 6650,
                "end": 6664,
                "name": "Los Alamos HIV"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In our validation set, we see a C present at around 50% of called bases at both these positions in raw data but this region is trimmed by the ARTIC pipeline and is therefore not used to call variants and contribute to the final consensus sequence."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The resultant coronavirus disease 2019 (COVID‐19) manifests predominantly symptoms in the lower respiratory system, typically presented as viral pneumonia."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Suspected COVID‐19 patients who had documented history of exposure and exhibited symptoms, but did not have positive polymerase chain reaction (PCR) test results, were generally self‐quarantined."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Some patients had a contact history with a confirmed COVID‐19 patient but did not have typical viral pneumonia symptoms or fever, and so did not get selected for PCR testing."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Given the rapidly growing pandemic and the overwhelmed medical system, a number of patients with typical COVID‐19 symptoms could not be hospitalized, even if they were tested positive by PCR."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The combination of the false negative rate of PCR testing, the biased pre‐screening procedure for patients to get tested, and hospital space limitation results in an increasing number of nonhospitalized COVID‐19 patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Most of the prescribed alternative medicines are, however, neither specific nor highly effective for COVID‐19 treatment."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The outbreak of COVID‐19 in Wuhan, China, in January 2020, was the first strike on public health system by SARS‐CoV‐2."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Patients infected with COVID‐19 had a high chance of developing severe pneumonia and acute respiratory distress syndrome (16%‐17%) and the mortality rate was high (4.3%‐11%)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            ", ",
            ", ",
            ", ",
            " Hospitalization became the only possible way for severe COVID‐19 patients to receive medical supports and treatment against symptoms."
        ],
        "lab": [
            false,
            false,
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A number of patients in Wuhan had documented contact histories with confirmed COVID‐19 patients and also showed respiratory symptoms, however unfortunately, their upper respiratory system did not have viral loads that were high enough to pass the PCR test threshold, and so they did not have a positive PCR test result to qualify for hospitalization in January and early February in Wuhan."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Our medical team tracked and helped treat a number of these nonhospitalized COVID‐19 patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "On Feb 2nd (day 22), the patient's fingertip oxygen saturation dropped to 93% (comparable to severe COVID‐19 patients) and routine blood examination showed elevated level of C‐reactive protein (50.02 in patient, vs normal ranges at 0‐4) (Table 1)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Given the patient's history of contact with confirmed COVID‐19 patients and her typical COVID‐19 symptoms, the most possible infection at the time was SARS‐CoV‐2."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "During late January and early February, the protocol for COVID‐19 clinical diagnosis and patient admission used in China required a confirmation of infection by RT‐PCR positive result, and thus this patient was not eligible for hospitalization at that moment."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This patient with suspected COVID‐19 was sent home for self‐quarantine."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Given that the medicines prescribed in the hospital failed to relieve the patient's symptoms and started to trigger side effects, and that the patient was not eligible for COVID‐19 treatment in the hospital, all prescribed medicines were discontinued."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Thus far for COVID‐19, there are no pharmacological treatment regimens of proven efficacy."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Immunopathology is a leading cause of morbidity and mortality in severe COVID‐19 patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "There is an urgent need for treatment regimens that can manage inflammation and tissue damages associated with severe COVID‐19, to reduce mortality and buy time for the immune system to clear the virus from the patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "During the initial COVID‐19 outbreak in Wuhan, corticosteroid has been used in hospitals to suppress lung inflammation in COVID‐19 patients,",
            " however, multiple side effects have been observed."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Here we report DG, a marketed Chinese traditional medicine with a steroid‐like effect, in combination with VC as a potential anti‐inflammatory treatment to relieve severe symptoms from COVID‐19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Our article here reports a case of nonhospital COVID‐19 that showed significantly positive responses to DG treatment."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Although the exact functions of DG against SARS‐CoV‐2 infection and the associated immunopathology await further investigations, it is possible that the therapeutic effects of DG observed in this severe COVID‐19 patient were a combinatory result of the antiviral and anti‐inflammatory effects of DG in the respiratory and neurological systems."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Given these encouraging pharmacological effects and the demonstrated safety, as well as the low cost and wide availability of DG and VC, we suggest that a combination of these might be a good candidate for alternative medicine against COVID‐19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Implementation of this treatment regimen might worth more attention, and further investigations in clinical trials can be considered to validate its effects in relieving severe symptoms and reducing mortality of COVID‐19 in a larger cohort."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "For suspected COVID‐19 patients who cannot be hospitalized and have no venues for COVID‐19 specific prescriptions, we suggest that the combination of DG and VC may be a promising candidate as an alternative medicine to help relieve severe symptoms of COVID‐19 during self‐quarantine."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Abstract  SARS‐CoV‐2 is highly infectious, and infection by this virus results in COVID‐19, manifesting predominantly symptoms in the lower respiratory system."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Suspected COVID‐19 patients who had a documented history of exposure and exhibited symptoms, but did not have positive PCR test results, were generally self‐quarantined with prescriptions aiming to help attenuate their symptoms."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These prescriptions are however neither specific nor highly effective for COVID‐19 treatment."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We report here a case of severe COVID‐19 that never had a positive PCR test result during disease progression but was confirmed with antibody test post recovery."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This patient went through severe COVID‐19 but eventually recovered upon the implementation of this treatment regimen, suggesting potential therapeutic effects of DG as alternative medicine to help relieve COVID‐19 symptoms."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We report here a case of severe COVID‐19, in which diammonium glycyrrhizinate and vitamin C were used as alternative medicine to help relieve COVID‐19 symptoms."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We carried out SARS-CoV-2 RNA detection by two first-line real-time reverse transcription (RT)-PCR assays [9], one of which (SpikeP_ps80) was developed in-house as soon as the first SARS-CoV-2 genome (",
            "GenBank",
            " Accession no. ",
            "MN908947",
            ") was released by Chinese teams (on January 10, 2020)."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 201,
                "end": 208,
                "name": "GenBank"
            },
            false,
            {
                "id": "T2",
                "type": "AccessionNumber",
                "start": 223,
                "end": 231,
                "name": "MN908947"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T1",
                "end": "T2"
            }
        ]
    },
    {
        "sen": [
            "At 7:00 pm the same day, after a run of 4 h on the GridION X5 instrument (Oxford Nanopore Technologies Ltd., Oxford, UK), we were able to obtain using the CLC Genomics tool (https://digitalinsights.qiagen.com/), by mapping 42 reads with an average length of 1433 nucleotides on a set of coronavirus genomes from the ",
            "Virus Pathogen Database and Analysis Resource",
            " [11], a 18,611-nucleotide-long consensus sequence corresponding to approximately 62% of the viral genome (",
            "EMBL",
            " Accession no. ",
            "ERS4366776",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T3",
                "type": "Repository",
                "start": 602,
                "end": 647,
                "name": "Virus Pathogen Database and Analysis Resource"
            },
            false,
            {
                "id": "T4",
                "type": "Repository",
                "start": 754,
                "end": 758,
                "name": "EMBL"
            },
            false,
            {
                "id": "T5",
                "type": "AccessionNumber",
                "start": 773,
                "end": 783,
                "name": "ERS4366776"
            },
            false
        ],
        "rel": [
            {
                "id": "R2",
                "bool": true,
                "head": "T4",
                "end": "T5"
            }
        ]
    },
    {
        "sen": [
            "This sequence, by similarity search using the BLASTn tool [12] against the ",
            "NCBI",
            " nucleotide sequence database (",
            "GenBank",
            "), found as best hit the genome of a SARS-CoV-2 (",
            "GenBank",
            " Accession no."
        ],
        "lab": [
            false,
            {
                "id": "T6",
                "type": "Repository",
                "start": 861,
                "end": 865,
                "name": "NCBI"
            },
            false,
            {
                "id": "T7",
                "type": "Repository",
                "start": 896,
                "end": 903,
                "name": "GenBank"
            },
            false,
            {
                "id": "T8",
                "type": "Repository",
                "start": 952,
                "end": 959,
                "name": "GenBank"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A total of 18,585 reads could be mapped on the SARS-CoV-2 genome ",
            "GenBank",
            " Accession no."
        ],
        "lab": [
            false,
            {
                "id": "T9",
                "type": "Repository",
                "start": 1039,
                "end": 1046,
                "name": "GenBank"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Over the study period (January 6, 2020–April 14, 2020), there were 1333 laboratory-confirmed cases of COVID-19 in Victoria."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The majority of cases (827/1333, 62.0%) were identified in returning travelers, most commonly from north–west Europe and the Americas, and 360 (27.0%) in known COVID-19 contacts (Table 1)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Almost all second-level lineages from a recently proposed SARS-CoV-2 genomic nomenclature were identified in the dataset (excluding lineage A.4), suggesting that Victorian samples were representative of the global diversity of published SARS-CoV-2 sequences, consistent with epidemiological findings (Fig. 3 and Table 1)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In total, 737 samples belonged to a genomic cluster, representing 81.6% of the samples in the final dataset."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Among our dataset, 4/76 (5%) genomic clusters had >50% of cases associated with a cruise ship (Fig. 4)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "On manual inspection, at least one sequence from each pair was found to have more ambiguous or missing base calls than the rest of the dataset, potentially contributing to the high number of intra-patient SNPs."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition, recently proposed lineages were also determined for the dataset."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Here we report high-throughput genomics for SARS-CoV-2, sequencing 80% of cases in Victoria, Australia (population 6.24 million) between 6 January and 14 April 2020 (total 1,333 COVID-19 cases)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Additional sequence data and metadata are available at ",
            "https://github.com/MDU-PHL/COVID19-paper",
            "."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "URL",
                "start": 1387,
                "end": 1427,
                "name": "https://github.com/MDU-PHL/COVID19-paper"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The features of the 507 human samples in our dataset were used to show the patterns with the multidimensional scaling method."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Based on the GGAP (g = 3) feature, we computed the Euclidean distance of SARS-CoV-2 and SARS-CoV from other coronaviruses in the dataset to explore the evolution dynamic, separately."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "With the improvement of annotation in the database, the false rate could be reduced [19]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Moreover, we computed the Euclidean distance of SARS-CoV-2 and SARS-CoV from other coronaviruses in the dataset to explore the evolution dynamic."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The nomenclature for coronavirus in the dataset is provided as Additional file 1."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Pangolins have been identified, besides bats, as a possible source of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19) (10–14)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In silico translation of the pangolin IFIH1 pseudogene (",
            "GenBank",
            " gene ID: ",
            "108398082",
            ") and alignment of the resulting amino acid sequence to that of human IFIH1 showed numerous disruptive mutations (Figure S1A)."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 246,
                "end": 253,
                "name": "GenBank"
            },
            false,
            {
                "id": "T2",
                "type": "AccessionNumber",
                "start": 263,
                "end": 272,
                "name": "108398082"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T1",
                "end": "T2"
            }
        ]
    },
    {
        "sen": [
            "In silico translation of the pangolin ZBP1 pseudogene (",
            "GenBank",
            " gene ID: ",
            "108390931",
            ") and alignment of the resulting amino acid sequence to that of human ZBP1 showed premature termination of the translation product and lack of the carboxy-terminal half of the protein (Figure S1B)."
        ],
        "lab": [
            false,
            {
                "id": "T3",
                "type": "Repository",
                "start": 454,
                "end": 461,
                "name": "GenBank"
            },
            false,
            {
                "id": "T4",
                "type": "AccessionNumber",
                "start": 471,
                "end": 480,
                "name": "108390931"
            },
            false
        ],
        "rel": [
            {
                "id": "R2",
                "bool": true,
                "head": "T3",
                "end": "T4"
            }
        ]
    },
    {
        "sen": [
            "All datasets presented in this study are included in the article/Supplementary Material."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Objective  Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was detected in faeces of patients with COVID-19, the activity and infectivity of the virus in the GI tract during disease course is largely unknown."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We investigated temporal transcriptional activity of SARS-CoV-2 and its association with longitudinal faecal microbiome alterations in patients with COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We performed RNA shotgun metagenomics sequencing on serial faecal viral extractions from 15 hospitalised patients with COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Results  Seven (46.7%) of 15 patients with COVID-19 had stool positivity for SARS-CoV-2 by viral RNA metagenomic sequencing."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "ExoN increases the fidelity of RNA synthesis by correcting nucleotide incorporation errors made by RdRp [14]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "",
            "GISAID",
            " database (",
            "https://www.gisaid.org/",
            ") filtered from December 2019 up to March 13th, 2020 was used to collect 220 SARS-CoV-2 complete genomes of different patients all around the world (i.e. China, USA, Canada, Australia, United Kingdom, Germany, France, Japan, Italy, Switzerland, Singapore, Luxembourg, Netherlands, Spain, Portugal, Sweden, Czech Republic, Thailand, India, Cambodia, Hong Kong, Finland, Singapore, and Ireland) taking into particular consideration those deposited during the development of European outbreaks."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 110,
                "end": 116,
                "name": "GISAID"
            },
            false,
            {
                "id": "T2",
                "type": "URL",
                "start": 127,
                "end": 150,
                "name": "https://www.gisaid.org/"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T1",
                "end": "T2"
            }
        ]
    },
    {
        "sen": [
            "We divided our dataset into 4 geographic areas: Asia, Oceania, Europe, North America (Fig. 1)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Moreover, we highlighted the presence of additional “conserved mutations” in all the geographic areas, taking into account only those occurring more than 10 times in our database."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In our database, the first appearance of a silent RdRp mutation (nt 14804) is manifested on February 9th, 2020 in UK (England), while a different RdRp mutation (nt 14408, amino acid P to L) is observed for the first time in Italy (Lombardy) on February 20th, 2020, when a dramatic increase of the number of European infected patients was reported from the WHO website [27]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Background  SARS-CoV-2 is a RNA coronavirus responsible for the pandemic of the Severe Acute Respiratory Syndrome (COVID-19)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We analyzed 220 genomic sequences from the ",
            "GISAID",
            " database derived from patients infected by SARS-CoV-2 worldwide from December 2019 to mid-March 2020."
        ],
        "lab": [
            false,
            {
                "id": "T3",
                "type": "Dataset",
                "start": 1460,
                "end": 1466,
                "name": "GISAID"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "SARS-CoV-2 reference genome was obtained from the ",
            "GenBank",
            " database."
        ],
        "lab": [
            false,
            {
                "id": "T4",
                "type": "Repository",
                "start": 1619,
                "end": 1626,
                "name": "GenBank"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The datasets analysed during the current study are available in the ",
            "GISAID",
            " (",
            "https://www.gisaid.org/",
            ") and ",
            "GenBank",
            " (",
            "https://www.ncbi.nlm.nih.gov/nuccore/NC_045512",
            ") repositories."
        ],
        "lab": [
            false,
            {
                "id": "T5",
                "type": "Dataset",
                "start": 1705,
                "end": 1711,
                "name": "GISAID"
            },
            false,
            {
                "id": "T6",
                "type": "URL",
                "start": 1713,
                "end": 1736,
                "name": "https://www.gisaid.org/"
            },
            false,
            {
                "id": "T7",
                "type": "Repository",
                "start": 1742,
                "end": 1749,
                "name": "GenBank"
            },
            false,
            {
                "id": "T8",
                "type": "URL",
                "start": 1751,
                "end": 1797,
                "name": "https://www.ncbi.nlm.nih.gov/nuccore/NC_045512"
            },
            false
        ],
        "rel": [
            {
                "id": "R2",
                "bool": true,
                "head": "T5",
                "end": "T6"
            },
            {
                "id": "R3",
                "bool": true,
                "head": "T7",
                "end": "T8"
            }
        ]
    },
    {
        "sen": [
            "As of August 5, 2020, 18,566,769 persons with COVID-19 infection were reported in 188 countries and territories worldwide and resulting in 701,316 death [3]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This COVID-19 pandemic not just a global health crisis, but also affect the global economy system."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Therefore, Taiwan government took very quick reaction to prevent the spread of COVID-19 in Taiwan according to the previous experience dealing with SARS."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Taiwan still has a low incidence and very low death rate of COVID-19 compared with Europe and USA [5]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "But the situation of COVID-19 infection in the United States are still in the peak by mid-April, 2020."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "How to treat and prevent COVID-19 infection becomes the most important global health issues."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The governments of big countries, the big pharmaceutical companies, the major scientific laboratories all have made big investment for the treatment of COVID-19 currently."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Since Taiwan has many academic institutes and industries good in the biotechnology and pharmaceutical fields, it is a very good time point for Taiwan to develop quick diagnosis kits, new drugs and vaccines for COVID-19 infection."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Therefore, after Taiwan start to have COVID-19 patients in January, 2020, the Minister of Health and Welfare requested National Health Research Institutes (NHRI) to take the responsibility in coordinating the research in the treatment and prevention of COVID-19 infection in Taiwan."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To collect the COVID-19 biosamples in accordance with the Human Biobank Management Act [6]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The Ethic Committee of NHRI Biobank quickly designed and approved a new non-tumor informed consent form (ICF) for COVID-19 patients on Feb. 13."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "For recruitment of COVID-19 patients and collect specimen from all hospitals in Taiwan, we need to have a connection with all major hospitals, since we did not know COVID-19 patients were hospitalized in which hospitals."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "On Feb.27, The Department of Medical Affairs of MOHW forward the official letter of NBCT to all hospitals at or above the regional level in Taiwan urging all medical institutes to collaborate for collection of biosamples of COVID-19 patients and to accelerate the research of COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "On March 1, we received the first COVID-19 patient blood samples immediately."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We also quickly received the first application for COVID-19 serum samples on March 17 and got approved in April."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "NHRI President Liang rapidly approved the usage of a new laboratory exclusively for NHRI Biobank to store and handling the COVID-19 biosamples."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition, it also needs to have a biosafety cabinet (BSC) for handling the COVID-19 biosamples."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "For opening this P2 lab, and to handle the COVID-19 human biosamples, we need to apply for the permission of NHRI Biosafty Committee."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This special P2 laboratory was completely set up and got permission to work in 2 weeks, just before we received the first COVID-19 human samples on March 1, 2020."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Since COVID-19 patients in Taiwan was few (only 32 cases reported when the P2 laboratory was established), and these patients distributed diversely across Taiwan."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This NHRI COVID-19 Biobank will also conduct value-added analyses of the collected blood samples, including DNA whole genome sequencing and RNA sequencing."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "By August 5, 2020, this COVID-19 biobank has collected 165 blood samples of 110 patients from more than 10 hospitals across north, middle and south part of Taiwan, including both COVID-19 (+) and (−) pneumonia patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "However, since Taiwan already have reported 476 COVI-19 cases as of August 5, 2020 [5], the current recruitment of COVID-19 patients is still not satisfactory."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We are very grateful for the doctors and the medical personnel who spent the time and effort to help collect the specimens and all of the patients who are willing to donate their blood samples for COVID-19 research."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "By the request of the Minister of Health and Welfare, NHRI Biobank was assigned to establish a COVID-19 biobank in early Feb, 2020 to collect COVID-19 patients’ blood samples for Taiwan researchers and industries in an emergent way."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "By August 5, 2020, this COVID-19 biobank has collected 165 blood samples of 110 patients from more than 10 hospitals across north, middle and south part of Taiwan, including both COVID-19 (+) and (-) pneumonia patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This biobank can provide applicants with biosamples, such as serum, DNA and RNA, and also the clinical and genomic data, so as to accelerate the COVID-19 treatment and prevention research in Taiwan."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This COID-19 biobank already received 15 applications."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "It has become the most important research resource for the COVID-19 pandemic in Taiwan, including new screening reagents, disease mechanism, the variable human responses and epidemic preventions."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Paired-end reads (2 × 150 bp) were assembled into contigs and aligned to viral metagenomic database comprising all viral reference sequences (all viral reference sequences in ",
            "NCBI",
            ": 12,209 strains)."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 175,
                "end": 179,
                "name": "NCBI"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In short, plasmid encoding wild-type (reference strain Amsterdam I, accession number: ",
            "NC_005831.1",
            ") or mutant HCoV-NL63 spike protein was transfected into 293 T cells, 24 h later transduced target cells were infected with rVSV-ΔG-luc, viral supernatant was harvested 24 h after transduction."
        ],
        "lab": [
            false,
            {
                "id": "T2",
                "type": "AccessionNumber",
                "start": 284,
                "end": 295,
                "name": "NC_005831.1"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To investigate the biological relevance of I507 L mutation in spike RBD, pseudotyped HCoV-NL63 were generated bearing WT (reference strain Amsterdam I, accession number: ",
            "NC_005831.1",
            ") and I507 L mutant S protein."
        ],
        "lab": [
            false,
            {
                "id": "T3",
                "type": "AccessionNumber",
                "start": 659,
                "end": 670,
                "name": "NC_005831.1"
            },
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "5 days post transduction, mice were infected via the intranasal route with a 50% tissue culture infective dose (TCID50) at 1.5×105 TCID50·mL−1 of MERS-CoV EMC/2012. 50 mg·kg−1·day−1 CsA diluted in DMSO or DMSO alone were mixed with a nut/chocolate cream, and offered to the mice for voluntary uptake."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Oral application of CsA significantly reduced viral titres (3.45±0.15 versus 2.1±0.36 TCID50·mL−1 in the DMSO versus CsA group) at day 7 post MERS-CoV infection (figure 7c)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Oral application of CsA (50 mg·kg−1·day−1) or DMSO as solvent control was started at day 3 post transduction, while mice were infected with 1.5×105 TCID50·mL−1 MERS-CoV via the intranasal route at day 5 post transduction."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Lung homogenate was used to b) quantify relative IFNL2/3 mRNA and c) determine viral load by TCID50."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "TCID50: 50% tissue culture infective dose."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To discover BGCs encoding members of the FK506/rapamycin structural class (FK gene clusters), we developed a biosynthetic “search term” to query our microbial sequence database containing partial sequences of pooled DNA samples from ∼135,000 Actinomycete species."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Pipecolate is incorporated in the final and shared step of FK506 and rapamycin assembly-line biosynthesis (19, 20) and directly binds the FKBP active site."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Once we identified genetic matches to the search term in our fragmentary sequence database, we identified the candidate Actinomycete strains harboring putative FK gene clusters."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition to CEP250, 11 other targets were identified in the proteomic target-identification (ID) screen of FKBP12–WDB002, albeit less reproducibly and with significantly lower spectral counts than CEP250 (Fig. 2), suggesting that they either bind weakly to FKBP12:WDB002, or they are associated with the complex containing CEP250."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We report the structure of CEP25011.4 bound to FKBP12 in the presence of WDB002 (Fig. 3, ",
            "Protein Data Bank [PDB]",
            " ID ",
            "6OQA",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 1021,
                "end": 1044,
                "name": "Protein Data Bank [PDB]"
            },
            false,
            {
                "id": "T2",
                "type": "AccessionNumber",
                "start": 1048,
                "end": 1052,
                "name": "6OQA"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T1",
                "end": "T2"
            }
        ]
    },
    {
        "sen": [
            "In a recent cellular protein interactome screen for SARS-CoV-2, the causative agent of COVID-19 disease, CEP250 was identified as a host factor that is engaged by the viral Nsp13 protein (42), suggesting the possibility that WDB002 may carry inhibitory activity against SARS-CoV-2 by binding to CEP250."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Finally, since WDB002 targets CEP250, it may be a promising starting point for developing a treatment for COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "As CEP250 was recently found to be an interaction partner with the Nsp13 protein of the SARS-CoV-2 virus that causes COVID-19 disease, it is possible that WDB002 or an analog may exert useful antiviral activity through its ability to form high-affinity ternary complexes containing CEP250 and FKBP12."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Only a few weeks after the first case of coronavirus disease 2019 (COVID-19) was reported in Wuhan, China, the first case of COVID-19 was confirmed in the Republic of Korea on January 20, 2020."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "On February 18, when a suspicious index case was identified in a religious group, a sharp increase in the number of COVID-19 cases was observed, with most infections being reported in specific clusters and geographic regions; the highest number of COVID-19 cases was reported in Daegu, followed by Gyeongbuk.1, 2, 3 Until April 4, 2020, 10,156 cumulative cases of COVID-19 were reported in Korea."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "It is well established that most patients with COVID-19 have fever along with respiratory symptoms, and human-to-human transmission occurs among close contacts, mainly through respiratory droplets and direct contact."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            ",",
            "Hence, the GI symptoms and fecal viral shedding in prolonged respiratory shedders with asymptomatic or mild COVID-19, who were in quarantine for more than a month, must be evaluated."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We conducted a prospective cohort study involving the patients diagnosed with asymptomatic or mild COVID-19, quarantined between April 4 and April 24 at the Youngdeok Samsung Living and Treatment Center (LTC)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Patients were defined as having asymptomatic or mild COVID-19 as per the Korea Centers for Disease Control and Prevention severity criteria (http://ncov.mohw.go.kr/en), when the following conditions were met: (1) age younger than 60 years, (2) no underlying chronic diseases, (3) alert mentality, (4) body temperature lower than 37.5°C, and (5) no radiologic evidence of pneumonia."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Originally, Youngdeok Samsung LTC was a human resource training center of Samsung, but on March 2, 2020, out-of-hospital quarantine and care for patients with asymptomatic or mild COVID-19 was mandated by the Korea Centers for Disease Control and Prevention."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Therefore, the accommodation facilities including Youngdeok Samsung human resource training centers were transformed to a LTC, and COVID-19 patients in Daegu and Gyeongbuk were quarantined there on March 4."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "COVID-19 was confirmed by real-time reverse-transcription polymerase-chain reaction (RT-PCR) assay for SARS-CoV-2 in upper respiratory tract specimens using nasopharyngeal and oropharyngeal swabs and/or lower respiratory tract specimens (ie, sputum)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "A total of 203 patients were diagnosed with COVID-19 between February 18 and March 1, 2020, and quarantined in the Youngdeok Samsung LTC on March 4, 2020."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Another group of 169 patients was diagnosed with COVID-19 between February 25 and March 8, 2020, and quarantined in the Gimje Samsung LTC."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The clinical characteristics of study participants with asymptomatic and mildly symptomatic COVID-19 are described in Table 1",
            "."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Fecal specimens were collected from April 4 to April 24, 2020 (21 days), and the median interval between COVID-19 diagnosis to the start of fecal sample collection was 37 days (range, 29–41 d) (Table 1, Figure 2",
            ")."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In a meta-analysis of 60 studies, comprising 4243 patients, the pooled prevalence rate of all GI symptoms was 17.6%, and when compared with the prevalence of GI symptoms according to the severity of COVID-19, pooled prevalence rates of GI symptoms were 11.8% and 17.1% in patients with nonsevere and severe COVID-19, respectively."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Background & Aims  Although coronavirus disease 2019 (COVID-19) is characterized by fever and respiratory symptoms, some patients have no or mild symptoms."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We investigated gastrointestinal symptoms and shedding of virus into feces of patients with asymptomatic or mild COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "We collected data from 46 patients (median age, 26 y; 46% men) with asymptomatic or mild COVID-19 (without fever and pneumonia) and prolonged respiratory shedding of SARS-CoV-2, quarantined from April 4, 2020, through April 24, 2020, in Korea."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The median interval between COVID-19 diagnosis to the start of fecal sample collection was 37 days (range, 29–41 d); 213 stool specimens were collected from 46 patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In an analysis of fecal and respiratory specimens from patients with COVID-19 in quarantine in Korea, we found that the gastrointestinal tract could be a route of transmission of SARS-CoV-2 even in patients with asymptomatic or mild disease, with no gastrointestinal symptoms."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In December 2019, a novel coronavirus disease (COVID-19) was identified in Wuhan, Hubei Province of China, and a previously unknown Betacoronavirus was subsequently isolated from patients with pneumonia [1]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In order to effectively control the COVID-19 outbreak, information regarding the period and routes of infectious virus shedding in patients is essential."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In general, droplets and close contact with infected respiratory secretions are considered the main transmission routes of the SARS-CoV-2; however, faecal–oral transmission has also been suggested since some COVID-19 patients have gastrointestinal symptoms, and viral RNA has been detected in oral and anal swabs from patients [[5], [6], [7], [8], [9]]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Briefly, viral RNA was extracted from clinical specimens of COVID-19 patients using the QIAamp Viral RNA Mini kit (QIAGEN, Hilden, Germany) and cDNAs were generated by reverse transcription using QuantiTect Reverse Transcription (QIAGEN, Hilden, Germany) according to the manufacturer's instructions."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "All PCR products regardless of whether ferret or human clinical specimens were sequenced and compared with the SARS-CoV-2 reference genome (",
            "GISAID",
            " accession ID: ",
            "EPI_ISL_407193",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Dataset",
                "start": 1157,
                "end": 1163,
                "name": "GISAID"
            },
            false,
            {
                "id": "T2",
                "type": "AccessionNumber",
                "start": 1178,
                "end": 1192,
                "name": "EPI_ISL_407193"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T1",
                "end": "T2"
            }
        ]
    },
    {
        "sen": [
            "Their underlying diseases, COVID-19 severity and treatment courses are summarized in Table 1",
            "."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Serum IgG antibody responses of all COVID-19 patients are described in Table 2",
            "."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "These symptom-recovered COVID-19 patients (patients 1, 2, 3 and 5) showed positive qPCR results in their urine specimens with viral RNA titres ranging from 1.08 ± 0.16 to 2.09 ± 0.85 log10 copies/mL. Further, in faecal specimens from patients 2, 4 and 5 (n = 3) SARS-CoV-2 RNA was detected at 1.17 ± 0.32, 2.18 ± 0.11 log10 copies/mL and 2.01 ± 0.28 log10 copies/mL, respectively."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In this study, we found that viable SARS-CoV-2 can be shed through various clinical specimens, such as saliva, stool and urine, of COVID-19 patients even at 15 days after onset of clinical symptoms."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In addition, we demonstrated the infectivity of saliva, urine and stool specimens from COVID-19 patients using cell culture and an animal model."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Given the consistent detection and isolation of SARS-CoV-2 RNA from saliva in another study [14], saliva could be an important non-invasive specimen for diagnosis and virus isolation in COVID-19 patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "However, despite several attempts [[18], [19], [20]], only one study thus far has demonstrated the presence of the infectious virus in faecal specimens from COVID-19 patients during the reviewing process for this study [18]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The aim was to determine whether various clinical specimens obtained from COVID-19 patients contain the infectious virus."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To demonstrate whether various clinical specimens contain the viable virus, we collected naso/oropharyngeal swabs and saliva, urine and stool samples from five COVID-19 patients and performed a quantitative polymerase chain reaction (qPCR) to assess viral load."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Further, viable SARS-CoV-2 was isolated from naso/oropharyngeal swabs and saliva of COVID-19 patients, as well as nasal washes of ferrets inoculated with patient urine or stool."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Discussion  Viable SARS-CoV-2 was demonstrated in saliva, urine and stool samples from COVID-19 patients up to days 11–15 of the clinical course."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Therefore, boosting the production of MGO into these cells by targeting deamidated HsTIM should deserve further studies as a potential therapy for COVID-19, even more considering that glycolysis sustains the SARS-CoV-2 replication and that its proteome is highly labile to MGO."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Here, we used the numbering of amino acid residues according to the translated product of the human TIM cDNA (",
            "GenBank",
            " Accession Number: ",
            "M10036.1",
            ")."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 388,
                "end": 395,
                "name": "GenBank"
            },
            false,
            {
                "id": "T2",
                "type": "AccessionNumber",
                "start": 414,
                "end": 422,
                "name": "M10036.1"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T1",
                "end": "T2"
            }
        ]
    },
    {
        "sen": [
            "The atomic coordinates of WT and N16D HsTIM (",
            "PDB",
            " IDs: ",
            "2JK2",
            " and ",
            "4UNK",
            ", respectively) were submitted to the PDBsum server (PDBsum-EMBL-EBI) to analyze the protein–protein contacts (interface) and tunnel formation (MOLEonline 2.0)."
        ],
        "lab": [
            false,
            {
                "id": "T3",
                "type": "Repository",
                "start": 470,
                "end": 473,
                "name": "PDB"
            },
            false,
            {
                "id": "T4",
                "type": "AccessionNumber",
                "start": 479,
                "end": 483,
                "name": "2JK2"
            },
            false,
            {
                "id": "T5",
                "type": "AccessionNumber",
                "start": 488,
                "end": 492,
                "name": "4UNK"
            },
            false
        ],
        "rel": [
            {
                "id": "R2",
                "bool": true,
                "head": "T3",
                "end": "T4"
            },
            {
                "id": "R3",
                "bool": true,
                "head": "T3",
                "end": "T5"
            }
        ]
    },
    {
        "sen": [
            "These results indicate that the incorporation of de novo negative charges in N16D HsTIM leads to important structural alterations in the interatomic network of contacts at the interface of the enzyme."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The N16D HsTIM incorporated a major number of DTNB molecules, which also docked deeper in the structure than those in the WT HsTIM (Figure 3)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Thus, an urgent requirement is to search for new treatments for COVID-19."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "They proposed their findings as evidence of vulnerability of SARS-CoV-2 to inactivation by MGO and as a scientific rationale for repurposing these antitumor agents for treatment of COVID-19 [54]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "This study elucidates the properties of deamidated HsTIM regarding its selective inhibition by thiol-reactive drugs and how these drugs can contribute to the development of cell-specific therapeutic strategies for a variety of diseases, such as COVID-19 and cancer."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "To this end, several academic, basic science research laboratories have already contributed to COVID-19 testing during the height of the pandemic (Vanuytsel et al., 2020, IGI Testing Consortium 2020)."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Please see Table 2 for US CDC panel recommended interpretations for diagnostic reporting for the one-step multiplex assay adapted from the TaqPath COVID-19 Combo Kit manual."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "When the COVID-19 pandemic first emerged at the end of 2019, there were many speculations about the potential impact and course of progression, but none would have imagined the speed and the scale of its spread and devastation to people's lives and livelihood across the global [1,2]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Despite the unprecedented efforts and rapid scientific progress in the discovery of the cellular and molecular details for the pathogenesis of COVID-19 as a result of SARS-COV2 infection, there are still no specific new therapies that have been approved to either prevent or treat COVID19 in clinics [1,2]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "However, new insights towards the pathogenesis of COVID19 have led to many efforts to repurpose existing drugs for the disease."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "While many of these repurposing attempts are aimed to interrupt the life-cycle of the SARS-COV2 virus infection or the ensuing systemic inflammatory injury, it is now clear that the adverse outcome of COVID19 can be strongly contributed by a number of pre-existing conditions, in particular hypertension and metabolic disorders."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "In recent retrospective studies led by a consortium of investigators based on a large clinical cohort of hospitalized COVID-19 patients in Hubei, China, one class of medicine originally used for blood pressure management (angiotensin-converting enzyme inhibitor or angiotensin-receptor blockers) [7], and another class of medication originally prescribed for hyperlipidemia (statins) [8], were analyzed for their association with COVID-19 related death and other secondary outcome."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "After extensive adjustment and matching for major clinical risk profiles, statistical analyses showed both ACEi/ARB and statins were found to be associated with a significant reduction in death and adverse outcome in hospitalized COVID-19 patients."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Nevertheless, it is emerging that several therapies originally approved to treat pre-existing conditions may bring clinical benefits to reduce death and severe complications in COVID-19 patients (Fig. 1",
            ")."
        ],
        "lab": [
            false,
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "The dataset comprised all currently available (n = 29) full genome sequences from the current (2019–2020) nCoV epidemic, as well as closely related (n = 2) bat strains (SARS-like CoV) retrieved from ",
            "NCBI",
            " (",
            "http://www.ncbi.nlm.nih.gov/genbank/",
            ") and ",
            "GISAID",
            " (",
            "https://www.gisaid.org/",
            ") databases."
        ],
        "lab": [
            false,
            {
                "id": "T1",
                "type": "Repository",
                "start": 199,
                "end": 203,
                "name": "NCBI"
            },
            false,
            {
                "id": "T2",
                "type": "URL",
                "start": 205,
                "end": 241,
                "name": "http://www.ncbi.nlm.nih.gov/genbank/"
            },
            false,
            {
                "id": "T3",
                "type": "Dataset",
                "start": 247,
                "end": 253,
                "name": "GISAID"
            },
            false,
            {
                "id": "T4",
                "type": "URL",
                "start": 255,
                "end": 278,
                "name": "https://www.gisaid.org/"
            },
            false
        ],
        "rel": [
            {
                "id": "R1",
                "bool": true,
                "head": "T1",
                "end": "T2"
            },
            {
                "id": "R2",
                "bool": true,
                "head": "T3",
                "end": "T4"
            }
        ]
    },
    {
        "sen": [
            "The complete dataset was assessed for presence of phylogenetic signal by applying the likelihood mapping analysis implemented in the IQ-TREE 1.6.8 software (http://www.iqtree.org) [8]."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    },
    {
        "sen": [
            "Both SS and PS estimators indicated the uncorrelated relaxed molecular clock (Bayes Factor = 4.3) as the best fitted model to the dataset under analysis."
        ],
        "lab": [
            false
        ],
        "rel": [
            "No Relation"
        ]
    }
]